Systems and methods for dynamic immunohistochemical profiling of biological disorders - Patents.com

JP2024501620A5Inactive Publication Date: 2024-12-05MT SINAI SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023533607
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-04
Filing Date
2021-12-03
Publication Date
2024-12-05
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides methods and systems for predicting a subject's diagnostic status for a disease or disorder, which may include staining a subject's tooth, hair, or nail sample to generate a stained tooth sample, analyzing fluorescence intensity spatially across the stained tooth, hair, or nail sample, and predicting the subject's diagnostic status for the disease or disorder based at least in part on the analysis of the fluorescence intensity.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 63 / 121,792, filed December 4, 2020, which is incorporated by reference in its entirety herein. [Background technology]

[0002] Dynamic biological responses may represent fundamental biological processes that are structurally and functionally important to humans. For example, abnormal or abnormal dynamic biological responses may be associated with many biological conditions, such as diseases and disorders. Examples of such biological conditions may include neurological conditions (e.g., autism spectrum disorder, schizophrenia, or attention-deficit / hyperactivity disorder (ADHD)), neurodegenerative conditions (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and Huntington's disease), and cancer (e.g., childhood cancer). Summary of the Invention

[0003] Given the above background, there exists a need for accurate methods and systems for the diagnosis of biological conditions, particularly non-invasive diagnosis. Such diagnosis may be based on accurate profiling of biomarkers detectable by non-invasive methods for the diagnosis of biological conditions. The present disclosure provides improved systems and methods for accurate diagnosis of biological conditions based on analysis of dynamic biological response data from biological samples obtained non-invasively from a subject. Such improved systems and methods for accurate diagnosis of biological conditions may be based on a combination of dynamic immunohistochemical profiling of biological samples and artificial intelligence data analysis of such dynamic profiles for the purpose of evaluating disease conditions. The present disclosure addresses these needs, for example, by providing biological sample biomarkers for the diagnosis of biological conditions. Biological samples include human biological samples associated with incremental growth. Such biological samples may be hair shafts, teeth, and nails. The non-invasive biomarkers of the present disclosure may be used for the diagnosis of young children, and in some cases, infants under the age of one.

[0004] In one aspect, the disclosure provides a method for predicting a subject's diagnostic status with respect to a disease or disorder, the method comprising: (a) staining a tooth sample of the subject to produce a stained tooth sample; (b) analyzing fluorescence intensity spatially across the stained tooth sample; and (c) predicting the subject's diagnostic status with respect to the disease or disorder based at least in part on the analysis of the fluorescence intensity.

[0005] In some embodiments, analyzing determines the temporal dynamics of an underlying biological process. In some embodiments, analyzing includes acquiring a fluorescent image of the stained tooth sample and analyzing the fluorescent intensity of the fluorescent image. In some embodiments, the fluorescent intensity varies spatially. In some embodiments, acquiring a fluorescent image of the stained tooth sample includes using an inverted or non-inverted confocal microscope. In some embodiments, staining the tooth sample includes using a C-reactive protein immunohistochemical stain. In some embodiments, the method further includes sectioning the tooth sample. In some embodiments, staining the tooth sample includes (1) cutting the tooth sample, (2) demineralizing the tooth sample, (3) sectioning the demineralized sample, (4) staining the demineralized tooth sections with primary and secondary antibodies, (5) measuring spatial antibody fluorescence using a confocal microscope, and / or (6) extracting a time profile of the fluorescent intensity.

[0006] In some embodiments, the disease or disorder comprises autism spectrum disorder (ASD), attention deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric kidney disease, kidney transplant rejection, pediatric cancer, or any combination thereof. In some embodiments, the disease or disorder comprises ASD. In some embodiments, the subject is a human. In some embodiments, the subject is an adult. In some embodiments, the subject is about 12 years old to about 5 years old. In some embodiments, the subject is less than about 12, 11, 10, 9, 8, 7, 5, 4, 3, 2, or 1 year old. In some embodiments, the subject is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 years old.

[0007] In some embodiments, analyzing comprises generating a time profile of inflammation based at least in part on the fluorescence intensity, and analyzing the time profile of inflammation, in some embodiments, at least a portion of the time profile of inflammation corresponds to a prenatal period of the subject.

[0008] In some embodiments, predicting the subject's diagnostic status for a disease or disorder comprises processing the fluorescence intensity using a trained model. In some embodiments, processing comprises extracting features from the fluorescence intensity (e.g., by recurrence quantification analysis) and analyzing the features using the trained model. In some embodiments, the trained model is selected from the group consisting of a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering algorithm, a supervised clustering algorithm, a regression algorithm, a gradient boosting algorithm (e.g., a gradient boosted implementation of a machine learning algorithm such as gradient boosted decision trees), and any combination thereof. In some embodiments, the trained model comprises a gradient boosted ensemble model. In some embodiments, the trained model is configured to process one or more features selected from the group consisting of recurrence rate, determinism, mean diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, propensity for recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, mean recurrence time, Shannon entropy in recurrence time, number of most likely mean diagonal lengths (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. In some embodiments, the one or more features are extracted by applying a recurrence quantification analysis (RQA) to a fluorescence intensity trace derived from the analysis of the sample. In some embodiments, the trained model is configured to process two or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof.

[0009] In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder using a model having at least about 70%, 75%, 80%, 85% or 90% sensitivity in predicting the diagnostic status for the disease or disorder across a suitable cohort population (such as those provided in the Examples section below).

[0010] In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder using a model having a sensitivity of up to about 70%, 75%, 80%, 85% or 90% in predicting the diagnostic status for the disease or disorder across a suitable cohort population.

[0011] In some embodiments, the method further comprises predicting a subject's diagnostic status for a disease or disorder using a model having a specificity of at least about 70%, 75%, 80%, 85%, or 90% in predicting a diagnostic status for a disease or disorder across a suitable cohort population.

[0012] In some embodiments, the method further comprises predicting a subject's diagnostic status for a disease or disorder using a model having a specificity of up to about 70%, 75%, 80%, 85%, or 90% in predicting a diagnostic status for a disease or disorder across a suitable cohort population.

[0013] In some embodiments, the method further comprises predicting a subject's diagnostic status for a disease or disorder using a model having a positive predictive value of at least about 70%, 75%, 80%, 85%, or 90% in predicting a diagnostic status for the disease or disorder across a suitable cohort population.

[0014] In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder using a model having a positive predictive value of up to about 70%, 75%, 80%, 85% or 90% in predicting the diagnostic status for the disease or disorder across a suitable cohort population.

[0015] In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder using a model having a negative predictive value of at least about 70%, 75%, 80%, 85%, or 90% in predicting the diagnostic status for the disease or disorder across a suitable cohort population.

[0016] In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder using a model having a negative predictive value of up to about 70%, 75%, 80%, 85%, or 90% in predicting the diagnostic status for the disease or disorder across a suitable cohort population.

[0017] In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder using a model predicting a diagnostic status for the disease or disorder having an area under the receiver operating characteristic curve (AUROC) of at least about 0.65, at least about 0.70, at least about 0.75, at least about 0.80, at least about 0.82, at least about 0.84, at least about 0.86, at least about 0.88, or at least about 0.90 for a suitable cohort population.

[0018] In another aspect, the disclosure provides a device comprising one or more processors and a memory storing one or more programs for execution by the one or more processors, the one or more programs including instructions for: (a) sampling each respective position in a plurality of locations along a baseline on a biological sample of a subject associated with c-reactive protein of the subject, thereby obtaining a plurality of fluorescence intensity measurements, where each fluorescence intensity measurement in the plurality of fluorescence intensity measurements corresponds to a different position in the plurality of locations, where each position in the plurality of locations represents a different growth period of the biological sample of the subject associated with c-reactive protein; (b) analyzing each fluorescence intensity across the baseline on the biological sample, thereby obtaining a first data set; (c) deriving a respective second data set from a corresponding plurality of fluorescence intensity measurements, where each respective feature in a corresponding set of features is determined by a variability in c-reactive protein fluorescence intensity; and (d) processing the features using the trained model to determine a likelihood that the subject has a disease or disorder associated with c-reactive protein. In some embodiments, each second data set is derived by applying a recurrence quantification analysis or related method to the corresponding plurality of fluorescence intensity measurements.

[0019] In some embodiments, the plurality of fluorescence intensity measurements are measured using an inverted or non-inverted confocal microscope. In some embodiments, the biological sample comprises a tooth sample. In some embodiments, the tooth sample is stained using a C-reactive protein immunohistochemical stain. In some embodiments, the instructions further comprise sectioning the tooth sample. In some embodiments, the instructions further comprise demineralizing the tooth sample. In some embodiments, the disease or disorder comprises autism spectrum disorder (ASD), attention deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric kidney disease, kidney transplant rejection, pediatric cancer, or any combination thereof. In some embodiments, the disease or disorder comprises ASD. In some embodiments, the subject is a human. In some embodiments, the human is about 12 years old to about 5 years old. In some embodiments, the subject is less than about 12, 11, 10, 9, 8, 7, 5, 4, 3, 2, or 1 year old. In some embodiments, the subject is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 years old. In some embodiments, analyzing comprises generating a time profile of inflammation based at least in part on the plurality of fluorescence intensity measurements, and analyzing the time profile of inflammation. In some embodiments, at least a portion of the time profile of inflammation corresponds to a prenatal period of the subject. In some embodiments, predicting the subject's diagnostic status for a disease or disorder comprises processing the plurality of fluorescence intensity measurements using a trained model. In some embodiments, the trained model is selected from the group consisting of a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering algorithm, a supervised clustering algorithm, a regression algorithm, a gradient boosting algorithm, and any combination thereof. In some embodiments, the trained model comprises a gradient boosted decision tree.In some embodiments, the trained model is configured to process one or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. In some embodiments, the trained model is configured to process two or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time (TT), maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof.

[0020] In another aspect, the disclosure provides a non-transitory computer readable storage medium and one or more computer programs embedded in the non-transitory computer readable storage medium, the one or more computer programs including instructions that, when executed by a computer system, cause the computer system to perform a method including: (a) sampling each respective position in a plurality of locations along a baseline on a biological sample of a subject associated with c-reactive protein of the subject, thereby obtaining a plurality of fluorescence intensity measurements, where each fluorescence intensity measurement in the plurality of fluorescence intensity measurements corresponds to a different position in the plurality of locations, where each position in the plurality of locations represents a different developmental period of the biological sample of the subject associated with c-reactive protein; (b) analyzing each fluorescence intensity across the baseline on the biological sample, thereby obtaining a first data set; (c) deriving a respective second data set from the corresponding plurality of fluorescence intensity measurements, where each respective feature in a corresponding set of features is determined by successive variations in c-reactive protein fluorescence intensity; and (d) processing the features using the trained model to determine a likelihood that the subject has a disease or disorder associated with c-reactive protein. In some embodiments, each second data set is derived by applying a recurrence quantification analysis or related method to the corresponding plurality of fluorescence intensity measurements.

[0021] In some embodiments, the plurality of fluorescence intensity measurements are measured using an inverted or non-inverted confocal microscope. In some embodiments, the biological sample comprises a tooth sample. In some embodiments, the tooth sample is stained using a C-reactive protein immunohistochemical stain. In some embodiments, the method further comprises sectioning the tooth sample. In some embodiments, the method further comprises demineralizing the tooth sample. In some embodiments, the disease or disorder comprises autism spectrum disorder (ASD), attention deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric kidney disease, kidney transplant rejection, pediatric cancer, or any combination thereof. In some embodiments, the disease or disorder comprises ASD. In some embodiments, the subject is a human. In some embodiments, the subject is less than 5 years old. In some embodiments, the subject is less than 1 year old. In some embodiments, analyzing comprises generating a time profile of inflammation based at least in part on the plurality of fluorescence intensity measurements, and analyzing the time profile of inflammation. In some embodiments, at least a portion of the inflammation time profile corresponds to a prenatal period of the subject. In some embodiments, predicting the subject's diagnostic status for a disease or disorder comprises processing a plurality of fluorescence intensity measurements using a trained model. In some embodiments, the trained model is selected from the group consisting of a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering algorithm, a supervised clustering algorithm, a regression algorithm, a gradient boosting algorithm, and any combination thereof. In some embodiments, the trained model comprises a gradient boosted decision tree.In some embodiments, the trained model is configured to process one or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. In some embodiments, the trained model is configured to process two or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time (TT), maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof.

[0022] In another aspect, the disclosure provides a method for training a model, comprising: in a computer system having one or more processors and a memory storing one or more programs for execution by the one or more processors, (a) for each respective training subject in the plurality of training subjects, where a first subset of the training subjects in the plurality of training subjects have a first diagnostic status corresponding to having a first biological state associated with c-reactive protein, and a second subset of the training subjects in the plurality of training subjects have a second diagnostic status corresponding to not having the first biological state associated with c-reactive protein, (i) sampling each respective position in a plurality of positions along a reference line on the subject's biological sample associated with the subject's c-reactive protein, thereby obtaining a plurality of fluorescence intensity measurements, where each fluorescence intensity measurement in the plurality of positions corresponds to a different position in the plurality of positions, and where each position in the plurality of positions corresponds to a different growth of the subject's biological sample associated with c-reactive protein. (ii) sampling a biological sample over a period of time representing a time period; (iii) deriving a respective second dataset from a corresponding plurality of fluorescence intensity measurements, where each respective feature in the corresponding set of features is determined by the variability in c-reactive protein fluorescence intensity; and (b) training an untrained or partially untrained model using (i) the corresponding set of features of the second dataset for each respective training subject in the plurality of training subjects and (ii) a corresponding diagnostic state of each training subject in the plurality of training subjects selected from among a first diagnostic state and a second diagnostic state, thereby obtaining a trained model that provides an indication as to whether the test subject has a first biological state associated with c-reactive protein based on the values ​​of the features in the set of features obtained from the biological sample associated with c-reactive protein of the test subject.In some embodiments, each second data set is derived by applying a recurrence quantification analysis or related method to the corresponding plurality of fluorescence intensity measurements.

[0023] In some embodiments, the trained model is a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering model algorithm, a supervised clustering model algorithm, a regression model, a gradient boosting algorithm (e.g., a gradient boosted implementation of a machine learning algorithm such as gradient boosted decision trees), or any combination thereof. In some embodiments, the trained model comprises a gradient boosted ensemble model. In some embodiments, the trained model predicts an outcome for a multinomial distribution. In some embodiments, the trained model predicts an outcome for a binomial distribution. In some embodiments, the first biological condition associated with c-reactive protein is selected from the group consisting of autism spectrum disorder (ASD), attention deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric kidney disease, kidney transplant rejection, and pediatric cancer.

[0024] In some embodiments, evaluating the test subject for a first biological state associated with c-reactive protein further comprises distinguishing between the presence of the first biological state associated with c-reactive protein and the absence of the first biological state associated with c-reactive protein. In some embodiments, evaluating the test subject for a first biological state associated with c-reactive protein further comprises distinguishing between the first biological state associated with c-reactive protein and a second biological state associated with c-reactive protein that is different from the first biological state associated with c-reactive protein. In some embodiments, the first biological state is an autism spectrum disorder and the second biological state is neurotypical, i.e., the absence of a neurodevelopmental disorder. In some embodiments, the first biological state is an autism spectrum disorder and the second biological state is attention-deficit / hyperactivity disorder. In some embodiments, the test subject is a human. In some embodiments, the human is about 12 years old to about 5 years old. In some embodiments, the subject is less than about 12, 11, 10, 9, 8, 7, 5, 4, 3, 2, or 1 year old. In some embodiments, the subject is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 years old. In some embodiments, the corresponding biological sample associated with the c-reactive protein of each training subject is selected from the group consisting of a hair shaft, a tooth, and a nail. In some embodiments, the corresponding biological sample associated with the c-reactive protein of each training subject is a hair shaft, and the reference line corresponds to a longitudinal direction of the hair shaft. In some embodiments, the corresponding biological sample associated with the c-reactive protein of each training subject is a tooth, and the reference line corresponds to a direction across the growth zone, including the neonatal line of the tooth. In some embodiments, the corresponding plurality of locations are arranged such that a first location in the corresponding plurality of locations along the corresponding biological sample associated with the c-reactive protein of each training subject corresponds to a location closest to the tip of the corresponding biological sample associated with the c-reactive protein of each training subject.In some embodiments, each trace in the corresponding plurality of fluorescence intensity measurements includes a plurality of data points, each data point being an instance of a respective location in the plurality of locations. In some embodiments, the corresponding set of features is selected from the group consisting of recurrence rate, determinism, mean diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, propensity for recurrence, lamellarity, trapping time, maximum vertical line length, Shannon entropy in vertical line length, mean recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. In some embodiments, the features are derived from a recurrence quantification analysis or related computational analysis of the fluorescent traces. In some embodiments, the corresponding plurality of positions includes at least 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000, 10000, 12000, 14000, 16000, 18000, 20000, or more than 20000 positions.

[0025] Another aspect of the present disclosure provides a non-transitory computer-readable medium containing machine-executable code that, when executed by one or more computer processors, performs any of the methods described above or elsewhere herein.

[0026] Another aspect of the present disclosure provides a system including one or more computer processors and a computer memory coupled to the computer processors, the computer memory including machine executable code that, when executed by the one or more computer processors, performs any of the methods described above or elsewhere herein.

[0027] Further aspects and advantages of the present disclosure will become readily apparent to those skilled in the art from the following detailed description, in which only illustrative embodiments of the present disclosure are shown and described. As will be understood, the present disclosure is capable of other different embodiments, and its several details are capable of modification in various obvious respects, all without departing from the present disclosure. Thus, the drawings and description should be regarded as illustrative in nature, and not as restrictive.

[0028] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent that the publications and patents or patent applications incorporated by reference conflict with the disclosure contained herein, the specification is intended to supersede and / or take precedence over such conflicting material. [Brief description of the drawings]

[0029] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also referred to herein as "figures"), in which:

[0030] [Figure 1] 1 illustrates an example block diagram of a computing device 100 of the present disclosure. [Figure 2A-2C] Illustrative diagrams of subject hair samples (FIG. 2A), tooth samples (FIG. 2B), and nail samples (FIG. 2C) are shown. [Diagram 3] 3 shows a flow chart of a method 300 for evaluating a subject for a biological condition. [Figure 4] 1 illustrates a computer system that is programmed or otherwise configured to carry out the methods provided herein. [Diagram 5]FIG. 1 shows an example of daily C-reactive protein profiles of a subject over time, where the y-axis indicates CRP intensity and the x-axis indicates developmental age. [Figure 6A-6B] Receiver operating characteristic (ROC) curves are shown to characterize the sensitivity and specificity of the method for diagnosing autism at various prediction thresholds using a model trained utilizing features derived from recurrent quantitative analysis of C-reactive protein profiles sampled prenatally and in early childhood (e.g., up to 1 year of age). The performance of the device is measured by calculating the area under the curve (AUC) of the ROC plot, which provides a measure of performance at various classification thresholds. Here, the AUC is 0.86, indicating robust and accurate predictive performance. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] While various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the present invention described herein may be used.

[0032] Dynamic biological responses may represent fundamental biological processes that are structurally and functionally important to humans. For example, abnormal or abnormal dynamic biological responses may be associated with many biological conditions, such as diseases and disorders. Examples of such biological conditions may include neurological conditions (e.g., autism spectrum disorder, schizophrenia, or attention-deficit / hyperactivity disorder (ADHD)), neurodegenerative conditions (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and Huntington's disease), and cancer (e.g., childhood cancer).

[0033] Given the above background, there exists a need for accurate methods and systems for the diagnosis of biological conditions, particularly non-invasive diagnosis. Such diagnosis may be based on accurate profiling of biomarkers detectable by non-invasive methods for the diagnosis of biological conditions. The present disclosure provides improved systems and methods for accurate diagnosis of biological conditions based on analysis of dynamic biological response data from biological samples obtained non-invasively from a subject. Such improved systems and methods for accurate diagnosis of biological conditions may be based on a combination of dynamic immunohistochemical profiling of biological samples and artificial intelligence data analysis of such dynamic profiles for the purpose of evaluating disease states. The present disclosure addresses these needs, for example, by providing biological sample biomarkers for the diagnosis of biological conditions. Biological samples include human biological samples associated with incremental growth. Such biological samples may be hair shafts, teeth, and nails. The non-invasive biomarkers of the present disclosure may be used for the diagnosis of young children, and in some cases, infants less than one year of age. In some cases, the children may be about 12 years to about 5 years of age. In some embodiments, the child is less than about 12, 11, 10, 9, 8, 7, 5, 4, 3, 2, or 1 year old. In some embodiments, the child can be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 years old.

[0034] In one aspect, the disclosure provides a method for predicting a subject's diagnostic status with respect to a disease or disorder, the method comprising: (a) staining a tooth sample of the subject to produce a stained tooth sample; (b) analyzing fluorescence intensity spatially across the stained tooth sample; and (c) predicting the subject's diagnostic status with respect to the disease or disorder based at least in part on the analysis of the fluorescence intensity.

[0035] In some embodiments, analyzing includes acquiring a fluorescent image of the stained tooth sample and analyzing the fluorescent intensity of the fluorescent image. In some embodiments, acquiring a fluorescent image of the stained tooth sample includes using an inverted or non-inverted confocal microscope. In some embodiments, staining the tooth sample includes using a C-reactive protein immunohistochemical stain. In some embodiments, the method further includes sectioning the tooth sample. In some embodiments, staining the tooth sample includes demineralizing the tooth sample.

[0036] In some embodiments, the systems and methods disclosed herein may use C-reactive protein fluorescent immunohistochemistry staining alone or in combination with other techniques. Such techniques may include laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS), Raman spectroscopy, or any combination thereof. In some embodiments, combining techniques may improve the diagnostic accuracy or precision of a given technique alone. In some embodiments, the addition of LA-ICP-MS may provide multiple non-invasive metal metabolism biomarkers of a given biological sample that may complement the diagnostic power of C-reactive protein fluorescent immunohistochemistry data. In some embodiments, the metal metabolism biomarkers may include zinc, tin, magnesium, copper, iodide, lithium, aluminum, phosphorus, sulfur, calcium, chromium, manganese, iron, cobalt, nickel, arsenic, strontium, cadmium, tin, iodine, barium, mercury, lead, bismuth, molybdenum, or any combination thereof. In some embodiments, the addition of Raman spectroscopy can provide multiple spectra indicative of physiological changes induced by disease or external stressors to complement the diagnostic power of C-reactive protein fluorescent immunohistochemistry data.

[0037] In some embodiments, the disease or disorder comprises autism spectrum disorder (ASD), attention deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric kidney disease, kidney transplant rejection, pediatric cancer, or any combination thereof. In some embodiments, the disease or disorder comprises ASD. In some embodiments, the subject is a human. In some embodiments, the subject is an adult. In some embodiments, the subject may be about 12 to about 5 years old. In some embodiments, the subject may be less than about 12, 11, 10, 9, 8, 7, 5, 4, 3, 2, or 1 year old. In some embodiments, the subject may be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 years old.

[0038] In some embodiments, analyzing comprises generating a time profile of inflammation based at least in part on the fluorescence intensity, and analyzing the time profile of inflammation, in some embodiments, at least a portion of the time profile of inflammation corresponds to a prenatal period of the subject.

[0039] In some embodiments, predicting the subject's diagnostic status for a disease or disorder includes processing the fluorescence intensity using a trained model. In some embodiments, the trained model includes a plurality of parameters, where the term "parameter" refers to any coefficient or similarly any value of an internal or external element (e.g., weight and / or hyperparameter) in the model that can affect (e.g., modify, tune, and / or adjust) one or more inputs, outputs, and / or functions in the model (e.g., if the model is a regressor or classifier). For example, in some embodiments, a parameter of a model refers to any coefficient, weight, and / or hyperparameter that can be used to control, modify, tune, and / or adjust the behavior, learning, and / or performance of the model. In some examples, a parameter is used to increase or decrease the influence of an input (e.g., a feature) to the model. As a non-limiting example, in some embodiments, a parameter is used to increase or decrease the influence of a node (e.g., a neural network), where the node includes one or more activation functions. The assignment of parameters to specific inputs, outputs, and / or functions of a model is not limited to any one paradigm of a given model, but may be used in any suitable model for desired performance. In some embodiments, the parameters have fixed values. In some embodiments, the values ​​of the parameters are manually and / or automatically adjustable. In some embodiments, the values ​​of the parameters are modified by a model validation and / or training process (e.g., by error minimization and / or backpropagation methods). In some embodiments, the models of the present disclosure include multiple parameters.In some embodiments, the plurality of parameters associated with a model (e.g., an untrained, partially trained, or fully trained model) is n parameters, where n>2, n>5, n>10, n>25, n>40, n>50, n>75, n>100, n>125, n>150, n>200, n>225, n>250, n>350, n>500, n>600, n>750, n>1,000, n>2,000, n>4,000, n>5,000, n>7,500, n>10,000, n>20,000, n>40,000, n>75,000, n>100,000, n>200,000, n>500,000, n>1×10. 6 , n ≥ 5 × 10 6 , or n ≧ 1×10 7 In some embodiments, n is 10,000 to 1×10 7 , 100,000~5×10 6 , or 500,000 to 1×10 6 It is.

[0040] In some embodiments, processing the fluorescence intensities using the trained model comprises extracting features from the fluorescence intensities (e.g., by recurrence quantification analysis) and analyzing the features using the trained model. In some embodiments, the trained model is selected from the group consisting of a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering algorithm, a supervised clustering algorithm, a regression algorithm, a gradient boosting algorithm (e.g., a gradient boosted implementation of a machine learning algorithm such as gradient boosted decision trees), and any combination thereof. In some embodiments, the trained model comprises a gradient boosted ensemble model. In some embodiments, the trained model is configured to process one or more features selected from the group consisting of recurrence rate, determinism, mean diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, propensity for recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, mean recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. In some embodiments, the one or more features are extracted by applying a recurrence quantification analysis (RQA) to a fluorescence intensity trace derived from the analysis of the sample. In some embodiments, the trained model is configured to process two or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof.

[0041] In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder with a sensitivity of at least about 80%. In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder with a specificity of at least about 80%. In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder with a positive predictive value of at least about 80%. In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder with a negative predictive value of at least about 80%. In some embodiments, the method further comprises predicting the subject's diagnostic status for the disease or disorder with an area under the receiver operating characteristic curve (AUROC) of at least about 0.80.

[0042] In another aspect, the disclosure provides a device comprising one or more processors and a memory storing one or more programs for execution by the one or more processors, the one or more programs including instructions for: (a) sampling each respective position in a plurality of locations along a baseline on a biological sample of a subject associated with c-reactive protein of the subject, thereby obtaining a plurality of fluorescence intensity measurements, where each fluorescence intensity measurement in the plurality of fluorescence intensity measurements corresponds to a different position in the plurality of locations, where each position in the plurality of locations represents a different growth period of the biological sample of the subject associated with c-reactive protein; (b) analyzing each fluorescence intensity across the baseline on the biological sample, thereby obtaining a first data set; (c) deriving a respective second data set from the corresponding plurality of fluorescence intensity measurements, where each respective feature in a corresponding set of features is determined by a successive variation in c-reactive protein fluorescence intensity; and (d) processing the features using the trained model to determine the likelihood that the subject has a disease or disorder associated with c-reactive protein. In some embodiments, each second data set is derived by applying a recurrence quantification analysis or related method to the corresponding plurality of fluorescence intensity measurements.

[0043] In another aspect, the disclosure provides a non-transitory computer readable storage medium and one or more computer programs embedded in the non-transitory computer readable storage medium, the one or more computer programs including instructions that, when executed by a computer system, cause the computer system to perform a method including: (a) sampling each respective position in a plurality of locations along a baseline on a biological sample of a subject associated with c-reactive protein of the subject, thereby obtaining a plurality of fluorescence intensity measurements, where each fluorescence intensity measurement in the plurality of fluorescence intensity measurements corresponds to a different position in the plurality of locations, where each position in the plurality of locations represents a different developmental period of the biological sample of the subject associated with c-reactive protein; (b) analyzing each fluorescence intensity across the baseline on the biological sample, thereby obtaining a first data set; (c) deriving a respective second data set from the corresponding plurality of fluorescence intensity measurements, where each respective feature in a corresponding set of features is determined by successive variations in c-reactive protein fluorescence intensity; and (d) processing the features using the trained model to determine a likelihood that the subject has a disease or disorder associated with c-reactive protein. In some embodiments, each second data set is derived by applying a recurrence quantification analysis or related method to the corresponding plurality of fluorescence intensity measurements.

[0044] In another aspect, the disclosure provides a method for training a model, comprising: a computer system having one or more processors and a memory storing one or more programs for execution by the one or more processors, the computer system including: (a) for each respective training subject in the plurality of training subjects, where a first subset of the training subjects in the plurality of training subjects have a first diagnostic status corresponding to having a first biological state associated with c-reactive protein, and a second subset of the training subjects in the plurality of training subjects have a second diagnostic status corresponding to not having the first biological state associated with c-reactive protein, (i) sampling each respective position in a plurality of positions along a reference line on the subject's biological sample associated with the subject's c-reactive protein, thereby obtaining a plurality of fluorescence intensity measurements, where each fluorescence intensity measurement in the plurality of positions corresponds to a different position in the plurality of positions, and where each position in the plurality of positions corresponds to a different position in the plurality of positions of the subject's biological sample associated with c-reactive protein; The present invention provides a method for obtaining a biological sample according to the present invention, the method comprising: (i) sampling a biological sample representing a growth period; (ii) analyzing each fluorescence intensity across a baseline on the biological sample, thereby obtaining a first data set; and (iii) deriving a respective second data set from a corresponding plurality of fluorescence intensity measurements, wherein each respective feature in the corresponding set of features is determined by the variability of c-reactive protein fluorescence intensity. The method further comprises: (a) training an untrained or partially untrained model using (i) the corresponding set of features of each respective second data set for each training subject in the plurality of training subjects and (ii) a corresponding diagnostic state of each training subject in the plurality of training subjects, the corresponding diagnostic state being selected from among a first diagnostic state and a second diagnostic state, thereby obtaining a trained model that provides an indication as to whether the test subject has a first biological state associated with c-reactive protein based on the values ​​of the features in the set of features obtained from the biological sample associated with c-reactive protein of the test subject.In some embodiments, each second data set is derived by applying a recurrence quantification analysis or related method to the corresponding plurality of fluorescence intensity measurements.

[0045] In some embodiments, the trained model is a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering model algorithm, a supervised clustering model algorithm, a regression model, a gradient boosting algorithm (e.g., a gradient boosted implementation of a machine learning algorithm such as gradient boosted decision trees), or any combination thereof. In some embodiments, the trained machine learning model comprises a gradient boosted ensemble model. In some embodiments, the trained model predicts an outcome for a multinomial distribution. In some embodiments, the trained model predicts an outcome for a binomial distribution. In some embodiments, the first biological condition associated with c-reactive protein is selected from the group consisting of autism spectrum disorder (ASD), attention deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric kidney disease, kidney transplant rejection, and pediatric cancer.

[0046] In some embodiments, evaluating the test subject for a first biological state associated with c-reactive protein further comprises distinguishing between the presence of the first biological state associated with c-reactive protein and the absence of the first biological state associated with c-reactive protein. In some embodiments, evaluating the test subject for a first biological state associated with c-reactive protein further comprises distinguishing between the first biological state associated with c-reactive protein and a second biological state associated with c-reactive protein that is different from the first biological state associated with c-reactive protein. In some embodiments, the first biological state is an autism spectrum disorder and the second biological state is neurotypical, i.e., the absence of a neurodevelopmental disorder. In some embodiments, the first biological state is an autism spectrum disorder and the second biological state is attention-deficit / hyperactivity disorder. In some embodiments, the test subject is a human. In some embodiments, the human can be between about 12 years old and about 5 years old. In some embodiments, the human may be less than about 12, 11, 10, 9, 8, 7, 5, 4, 3, 2, or 1 year old. In some embodiments, the human may be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 years old. In some embodiments, the corresponding biological sample associated with the c-reactive protein of each training subject is selected from the group consisting of a hair shaft, a tooth, and a nail. In some embodiments, the corresponding biological sample associated with the c-reactive protein of each training subject is a hair shaft, and the reference line corresponds to a longitudinal direction of the hair shaft. In some embodiments, the corresponding biological sample associated with the c-reactive protein of each training subject is a tooth, and the reference line corresponds to a direction across the growth zone, including the neonatal line of the tooth. In some embodiments, the corresponding plurality of locations are arranged such that a first location in the corresponding plurality of locations along the corresponding biological sample associated with the c-reactive protein of each training subject corresponds to a location closest to the tip of the corresponding biological sample associated with the c-reactive protein of each training subject.In some embodiments, each trace in the corresponding plurality of fluorescence intensity measurements includes a plurality of data points, each data point being an instance of a respective location in the plurality of locations. In some embodiments, the corresponding set of features is selected from the group consisting of recurrence rate, determinism, mean diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, propensity for recurrence, lamellarity, trapping time, maximum vertical line length, Shannon entropy in vertical line length, mean recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. In some embodiments, the features are derived from a recurrence quantification analysis or related computational analysis of the fluorescent traces. In some embodiments, the corresponding plurality of positions includes at least 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000, 10000, 12000, 14000, 16000, 18000, 20000, or more than 20000 positions.

[0047] Details of an exemplary system are described in conjunction with FIG. 1, which illustrates an example block diagram of a computing device 100 of the present disclosure. In some implementations, the device 100 includes one or more processing units CPU 102 (also referred to as a processor), one or more network interfaces 104, a user interface 106, a non-persistent memory 111, a persistent memory 112, and one or more communication buses 114 for interconnecting these components. The one or more communication buses 114 optionally include circuitry (sometimes referred to as a chipset) that interconnects and controls communication between the system components. The non-persistent memory 111 typically includes high-speed random access memory such as DRAM, SRAM, DDR RAM, ROM, EEPROM, flash memory, while the persistent memory 112 typically includes CD-ROM, digital versatile disk (DVD), or other optical storage, magnetic cassette, magnetic tape, magnetic disk storage, or other magnetic storage device, magnetic disk storage device, optical disk storage device, flash memory device, or other non-volatile solid-state storage device. The persistent memory 112 optionally includes one or more storage devices located remotely from the CPU 102. The persistent memory 112 and the non-volatile memory devices within the non-persistent memory 112 include non-transitory computer-readable storage media.In some implementations, the non-persistent memory 111 or alternatively the non-transitory computer-readable storage medium, possibly in conjunction with the persistent memory 112, stores the following programs, modules, and data structures, or a subset thereof: an optional operating system 116 that includes instructions for handling various basic system services and performing hardware dependent tasks; an optional network communication module (or instructions) 118 for connecting the system 100 with other devices and / or the communication network 104; an optional classifier training module 120 for training models for assessing subjects for biological conditions; and a training object classifier module 122 for training the one or more training objects 124, including feature data for the one or more training objects 124. the data store 122 includes an optional data store for a dataset for biological samples from the training subjects, where the feature data includes parameters associated with each of the features 126, and a diagnostic status 128 (e.g., an indication that each training subject has been diagnosed with a biological condition or has not been diagnosed with a biological condition), an optional classifier validation module 130 for validating the model that distinguishes between biological conditions, an optional data store 132 for datasets for biological samples from the validation subjects, e.g., as trained using the classifier training module 120, and an optional patient classification module 134 for classifying subjects having a biological condition.

[0048] In various implementations, one or more of the above identified elements are stored in one or more of the memory devices mentioned above and correspond to sets of instructions for performing the functions described above. The above identified modules, data, or programs (e.g., sets of instructions) need not be implemented as separate software programs, procedures, data sets, or modules, and thus various subsets of these modules and data may be combined or otherwise rearranged in various implementations. In some implementations, the non-persistent memory 111 optionally stores a subset of the above identified modules and data structures. Furthermore, in some embodiments, the memory stores additional modules and data structures not described above. In some embodiments, one or more of the above identified elements are stored in a computer system other than that of the visualization system 100, which computer system is addressable by the visualization system 100, so that the visualization system 100 may retrieve all or a portion of such data when needed.

[0049] In some embodiments, the system 100 is connected to or includes one or more analytical devices for performing chemical analysis. For example, the optional network communication module (or instructions) 118 is configured to connect the system 100 with the one or more analytical devices, for example, via the communication network 104. In some embodiments, the one or more analytical devices include a laser ablation inductively coupled plasma mass spectrometer (LA-ICP-MS), a fluorescence image sensor, or a Raman spectrometer.

[0050] 1 depicts a "system 100," the diagram is intended more as a functional description of various features that may be present in a computer system, rather than a structural schematic of the implementations described herein. In practice, and as will be recognized by those skilled in the art, items shown separately may be combined and some items may be separated. Additionally, while FIG. 1 depicts certain data and modules in non-persistent memory 111, some or all of these data and modules may be stored in persistent memory 112.

[0051] In some embodiments, the method of the present disclosure includes obtaining a biological sample (e.g., a single hair including a hair shaft). The subject may be a human. In some embodiments, the subject is a child aged 5 years or less (e.g., the child is aged 5 years, 4 years, 3 years, 2 years, 1 year, 9 months, 6 months, 3 months, or 1 month or less). In some embodiments, the subject is an adult. FIG. 2A shows an example of a hair sample of a subject including a hair shaft. The hair sample may simply be cut from the subject (e.g., with the aid of scissors). The method of obtaining the hair sample may be non-invasive. The hair sample obtained may have a minimum length of 1 cm (e.g., the hair sample is 1 cm, 2 cm, 3 cm, 4 cm, or 5 cm in length). The hair sample may include any part of the hair (e.g., the tip or the part between the tip and the hair follicle). There is no special requirement for the hair sample to include a hair follicle in particular. FIG. 2B shows an example of a tooth sample of a subject. FIG. 2C shows an example of a nail sample of a subject. In the example of nails or hair, obtaining a biological sample may refer to positioning a subject so that a nail or hair may be sampled. A nail sample may include a whole nail or a nail clipping.

[0052] In some embodiments, the obtained biological sample is pretreated, such as by washing and drying the biological sample with one or more solvents and / or surfactants. If the biological sample is hair, the hair sample may be washed in a solution of TRITON X-100® and ultra-pure metal-free water (e.g., MILLI-Q® water) and dried overnight in an oven (e.g., at 60° C.). Pretreatment may further include preparing the hair shaft for measurement by placing the hair shaft on a glass slide (e.g., a microscope glass slide) with an adhesive film (e.g., double-sided tape). The hair shaft may be positioned so that the hair shaft is substantially straight. The glass slide containing the hair shaft may be placed in or near a measurement system (e.g., a laser ablation inductively coupled plasma mass spectrometer (LA-ICP-MS), a fluorescence image sensor, or a Raman spectrometer) to perform the analysis. If the biological sample is a tooth or nail, the surface of the biological sample may be washed (e.g., with a surfactant, water, or one or more solvents). In some cases, the sample may be demineralized before, after, immediately prior to, or any combination of time frames relative to performing the analyses described elsewhere herein. In some cases, demineralizing the sample includes (a) immersing the tooth in a solution of ethylenediaminetetraacetic acid (EDTA), where the EDTA may have a pH of about 7.0 to about 7.4, for up to about 5 weeks, (b) weighing the tooth every other week, and (c) removing the sample when the weight of the tooth plateau changes. The sample may be placed in or near a measurement system (e.g., a laser ablation inductively coupled plasma mass spectrometer (LA-ICP-MS), a fluorescence image sensor, or a Raman spectrometer) for performing the analysis.

[0053] 3 shows a flowchart of a method 300 for evaluating a subject for a biological condition, such as a method for predicting a subject's diagnostic status with respect to a disease or disorder. The method 300 may include staining a tooth sample of the subject (as in act 302) to generate a stained tooth sample. The method 300 may then include analyzing the fluorescence intensity spatially across the stained tooth sample (as in act 304). The method 300 may then include predicting the subject's diagnostic status with respect to a disease or disorder based at least in part on the analysis of the fluorescence intensity (as in act 306).

[0054] In some embodiments, analyzing includes acquiring a fluorescent image of the stained tooth sample and analyzing the fluorescent intensity of the fluorescent image. In some embodiments, acquiring a fluorescent image of the stained tooth sample includes using an inverted or non-inverted confocal microscope. In some embodiments, staining the tooth sample includes using a C-reactive protein immunohistochemical stain. In some embodiments, the method further includes sectioning the tooth sample. In some embodiments, staining the tooth sample includes demineralizing the tooth sample.

[0055] In some embodiments, analyzing comprises generating a time profile of inflammation based at least in part on the fluorescence intensity, and analyzing the time profile of inflammation, in some embodiments, at least a portion of the time profile of inflammation corresponds to a prenatal period of the subject.

[0056] Measurement data may be collected from the biological sample at multiple positions along the biological sample in succession. In some embodiments, the multiple positions along the baseline of the biological sample include at least 100 positions (e.g., 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000, 10000, 12000, 14000, 16000, 18000, 20000, or more than 20000 positions). In some embodiments, the respective positions are adjacent to each other. In this manner, each region corresponding to a different position on the biological sample may thereby be associated with a dynamic (e.g., time-varying) abundance measurement. In some embodiments, the respective positions are separated by a predetermined distance. In some embodiments, sampling is performed along the baseline of the biological sample starting from the respective position closest to the tip of the biological sample, such as a hair sample (e.g., the position corresponding to the subject's youngest age). In general, as long as the direction of sampling is known, sampling can be done starting from the respective location closest to the tip or root, and the appropriate trained model is used for the analysis.

[0057] The sampling may generate a set of data points. Each set of data points may correspond to measurements (e.g., abundance or concentration) of a substance indicative of a dynamic biological response measured at multiple locations along the biological sample. Each location along the baseline of the biological sample may correspond to a particular development time of the biological sample.

[0058] In some embodiments, in the example of a dental biological sample, the baseline may include 240-510 days of growth (e.g., the period of crown formation depending on the type of tooth). In some embodiments, each position along the baseline may correspond to about 1 to about 0.5 micrometers. Alternatively, or in addition, the biological sample may include a hair shaft, where a position along the baseline corresponds to about 5 minutes of growth (e.g., the period of hair growth calculated using a resolution of 1 micrometer and an average rate of hair growth of 1 cm / month). A first data set including a plurality of traces is obtained by correlating multiple positions along the baseline of the biological sample to corresponding periods of growth. Each trace includes a time-dependent abundance measurement (e.g., abundance or concentration) of a substance indicative of a dynamic biological response measured from the biological sample. For example, the distance between the positions may correspond to an estimated growth (e.g., biological time) of the biological sample. For example, abundance may be measured for the dental sample along a distance of up to about 8 millimeters (mm), which corresponds to a biological time of about 240-510 days. Alternatively, or in addition, abundance can be measured for hair samples along a distance of 1.2 cm, which corresponds to a biological time of approximately 35 days. Biological time can be estimated by using the average rate of hair growth (e.g., 1 cm per month).

[0059] In some embodiments, data analysis may be performed on traces corresponding to time-dependent abundances (e.g., time-dependent concentrations) of substances indicative of dynamic biological responses measured from biological samples. This may include customized operations to clean up the data (e.g., smoothing the data over a time span and / or removing data points above or below a predefined threshold). In some embodiments, data analysis includes removing data points from the traces that have a mean absolute difference between adjacent data points that is at least 1, 2, or 3 standard deviations of the mean absolute difference between adjacent points.

[0060] In some embodiments, data analysis further includes normalizing each trace to an internal standard. For example, an analyte detected in a sample that was evenly incorporated during development / growth of the biological sample that does not vary with environmental exposure (e.g., diet) can serve as an internal standard.

[0061] In some embodiments, the data analysis further comprises performing a recurrence quantification analysis (RQA) on the time-dependent trace to obtain a set of features describing the dynamic periodic properties of the trace. The RQA measures the variability of the time-dependent trace. The RQA includes estimation of features describing the periodic properties in a given waveform, including determinism, entropy, mean diagonal length (MDL), laminarity, entropy, trapping time (TT), recurrence time (RT), Vmax, and Lmax, each of which captures different aspects of the signal dynamics, as described in the attached references. RQA methods and features are described, for example, by Webber et al., “Simpler Methods Do It Better: Success of Recurrence Quantification Analysis as a General Purpose Data Analysis Tool,” Physics Letters A 373, 3753-3756 (2009) and Marwan et al., “Recurrence Plots for the Analysis of Complex Systems,” Physics Reports 438, 237-239 (2007), the contents of each of which are incorporated herein by reference in their entirety. In some embodiments, the time-dependent traces are analyzed by using other analytical methods such as Fourier transforms, wavelet analysis, and cosinor analysis. Such techniques can be applied to derive similar metrics, including spectral analysis of frequency components and their associated powers. These metrics and related derivative measures can be used in place of RQA-derived features to analyze time-dependent traces obtained from biological samples for predictive classification purposes.

[0062] RQA involves the construction of recurrence plots to visualize and analyze the dynamic time structure of each acquired trace. Such recurrence plots can illustrate phase dynamic processes in continuous measurements by plotting a given sequence against the time-lag derivation of that sequence. From one-dimensional traces measured from the hair shaft, additional dimensions are computationally derived to embed the traces in a high-dimensional space called a phase diagram, where t refers to the value of the original trace and the dimensions (t+τ) and (t+2τ) are derived from delaying the original time series by an interval τ. Subsequent analysis is then performed on the embedded phase diagram to construct a recurrence plot and perform a recurrence quantification analysis. Recurrence plots can be derived from phase diagrams by applying a threshold function to each point in the phase diagram. On the corresponding recurrence plot, which consists of a square binary matrix usually represented as a white or black space, a given point is assigned a value of 1 at each time interval, and another point in the phase diagram shares the spatial limits of the assigned threshold boundary. The RQA method is applied to recurrence plots to examine the intervals of delay between states in a given system, with the black dots reflecting the time intervals when the system revisits the same state. Periodic processes in which the system continuously repeats a given pattern of states appear as black diagonal lines in the recurrence plot, while periods of stability appear as square structures, spurious repetitions appear as black dots, and unique events appear as white spaces.

[0063] In some embodiments, recurrence plots are constructed for traces of a single substance or a combination of two substances (e.g., to visualize interactive cyclic patterns of two substances, which may be referred to as cross-recurrence quantitative analysis, or joint recurrence quantitative analysis). In some embodiments, recurrence plots are constructed for combinations of three or more substances.

[0064] In some embodiments, the data analysis includes analyzing the recurrence plot to obtain a set of features associated with the recurrence plot. The features, which may be synonymously referred to as "rhythmic features" or "dynamic features", provide quantitative measures describing the periodicity, predictability, and transitionality present in the multiple traces. The features are selected from the set including recurrence rate, determinism, mean diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, lamellarity, trapping time, maximum vertical line length, Shannon entropy in vertical line length, mean recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), lamellarity, entropy, trapping time (TT), recurrence time (RT), Vmax, Lmax, and any combination thereof.

[0065] In some embodiments, the data analysis further comprises inputting the obtained set of features into a trained model. In some embodiments, the trained model comprises a predictive computation algorithm for obtaining a probability of the subject having the biological condition. In some embodiments, the predictive computation algorithm performs the following calculations:

number

[0066] Weight parameters β1, …, β kcan be defined based on model training. The probability p(subject) can be provided as a number ranging from 0 to 1, where 1 corresponds to a 100% probability that the subject has the biological condition.

[0067] In some embodiments, the data analysis includes applying a threshold to the obtained probability p(subject). If the obtained probability p(subject) is above the threshold, the subject is evaluated as having the biological condition. If the obtained probability is below the threshold, the subject is evaluated as not having the biological condition. In some embodiments, the threshold is about 0.3 to 0.6 (e.g., the predetermined threshold is about 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, or 0.6). The value assigned to the probabilistic threshold may be predefined or estimated during training of the model through the use of a receiver operating characteristic (ROC) chart, with the optimal threshold used corresponding to the value that results in the largest area under the curve (ROC-AUC). In some embodiments, the obtained probability is expressed in terms of associated odds (e.g., odds ratio (OR), which may be derived from the probability such as OR=p / (1-p)). For example, the evaluation includes evaluating the odds that the subject has the biological condition.

[0068] In some embodiments, the data analysis includes distinguishing the first biological condition from an alternative condition, e.g., a second biological condition. In some embodiments, the alternative condition is not associated with any known condition (e.g., neurotypical condition (NT)). In some embodiments, the first biological condition is associated with autism spectrum disorder (ASD) and the alternative condition is associated with attention-deficit / hyperactivity disorder (ADHD). In some embodiments, the alternative condition is any other neurodevelopmental condition, or a comorbid diagnosis of two neurodevelopmental conditions. Thus, the data analysis may be able to distinguish between the two neurodevelopmental conditions (e.g., distinguish between autism spectrum disorder and ADHD, or distinguish between ASD and comorbid (CM) cases diagnosed with both ASD and ADHD).

[0069] Healthcare providers, such as the patient's physician and treatment team, may have access to patient data (e.g., dynamic biological response data or other health data) and / or predictions or assessments generated from such data. Based on the data analysis results, the health care providers may determine clinical decisions or outcomes.

[0070] For example, a physician may prescribe that a patient undergo one or more clinical trials at a hospital or other clinical site based, at least in part, on a predicted disease or disorder in the subject. These prescribers may be provided when certain predetermined criteria (e.g., a minimum threshold for the likelihood of a disease or disorder) are met.

[0071] Such a minimum threshold can be, for example, at least about a 5% chance, at least about a 10% chance, at least about a 20% chance, at least about a 25% chance, at least about a 30% chance, at least about a 35% chance, at least about a 40% chance, at least about a 45% chance, at least about a 50% chance, at least about a 55% chance, at least about a 60% chance, at least about a 65% chance, at least about a 70% chance, at least about a 75% chance, at least about a 80% chance, at least about a 85% chance, at least about a 90% chance, at least about a 95% chance, at least about a 96% chance, at least about a 97% chance, at least about a 98% chance, or at least about a 99% chance.

[0072] As another example, a physician may prescribe a therapeutically effective amount of a therapeutic agent (e.g., a drug), clinical procedure, or further clinical trial to be administered to a patient based at least in part on a predicted disease or disorder in the subject. For example, a physician may prescribe an anti-inflammatory therapeutic agent in response to signs of inflammation in a patient.

[0073] Model The methods and systems of the present disclosure may utilize or access external capabilities of artificial intelligence techniques to develop signatures for various diseases or disorders. These signatures may be used to accurately predict diseases or disorders (e.g., months or years earlier than standard clinical care). Using such predictive capabilities, health care providers (e.g., physicians) may be able to make informed and accurate risk-based decisions, thereby improving the quality of care and monitoring provided to patients.

[0074] The disclosed methods and systems may analyze dynamic biological response data acquired from a subject (patient) to generate a probability that the subject has a disease or disorder. For example, the system may apply a trained (e.g., predictive) algorithm to the acquired dynamic biological response data to generate a probability that the subject has a disease or disorder. The trained algorithm may include an artificial intelligence-based model, such as a classifier or regressor, configured to process the acquired dynamic biological response data to generate a probability that the subject has a disease or disorder. The model may be trained using a clinical dataset from one or more cohorts of patients, for example, using the patient's clinical health data and / or dynamic biological response data as input and the patient's known clinical health outcome (e.g., disease or disorder) as output to the model.

[0075] The model may include one or more machine learning algorithms. Examples of machine learning algorithms may include support vector machines (SVM), naive Bayes classification, random forests, neural networks (e.g., deep neural networks (DNN), recurrent neural networks (RNN), deep RNN, long short-term memory (LSTM) recurrent neural networks (RNN), or gated recurrent units (GRU), or other supervised learning algorithms, or unsupervised machine learning, statistical, or deep learning algorithms for classification and regression. The model may also include estimation of an ensemble model consisting of multiple predictive models, and may utilize techniques such as gradient boosting, for example, in constructing gradient boosted decision trees. The model may be trained using one or more training datasets corresponding to patient data.

[0076] The training dataset may be generated, for example, from one or more cohorts of patients with common clinical characteristics (features) and clinical outcomes (labels). The training dataset may include a set of features and labels corresponding to the features. The features may correspond to algorithm inputs including dynamic biological response data, patient demographic information derived from electronic medical records (EMR), and medical observations. The features may include clinical characteristics, such as, for example, a particular range or category of dynamic biological response data. The features may include patient information, such as the patient's age, the patient's medical history, other medical conditions, current or past medications, and time since last observation. For example, a set of features collected from a given patient at a given time point may collectively act as a signature that may be indicative of the patient's health state or condition at the given time point.

[0077] For example, ranges of dynamic biological response data and other health measurements may be represented as multiple disjoint continuous ranges of continuous measurements, and categories of dynamic biological response data and other health measurements may be represented as multiple disjoint sets of measurements (e.g., {"high", "low"}, {"high", "normal"}, {"low", "normal"}, {"high", "borderline high", "normal", "low"}, etc.). Clinical features may also include clinical labels indicative of the patient's health history, such as a diagnosis of a disease or disorder, previous clinical treatments (e.g., drugs, surgical treatments, chemotherapy, radiation therapy, immunotherapy, etc.), behavioral factors, or other health conditions (e.g., hypertension or high blood pressure, hyperglycemia or high blood glucose, hypercholesterolemia or high blood cholesterol, history of allergic reactions or other side effects, etc.).

[0078] The label may include a clinical outcome, such as, for example, the presence, absence, diagnosis, or prognosis of a disease or disorder in a subject (e.g., a patient). The clinical outcome may include a temporal feature associated with the presence, absence, diagnosis, or prognosis of a disease or disorder in a patient. For example, the temporal feature may indicate that a patient developed a disease or disorder within a particular period of time after a previous clinical outcome (e.g., discharged from a hospital, administered a therapeutic agent such as a drug, received a clinical procedure such as a surgery, etc.). Such a period of time can be, for example, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 14 hours, about 16 hours, about 18 hours, about 20 hours, about 22 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 6 months, about 8 months, about 10 months, about 1 year, or more than about 1 year.

[0079] The input features may be structured by aggregating data into bins or alternatively using one-hot encoding. The input may also include feature values ​​or vectors derived from the inputs mentioned above, such as cross-correlations calculated between separate dynamic biological response data or other measurements over a fixed period of time, and discrete derivatives or finite differences between successive measurements. Such a period may be, for example, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 14 hours, about 16 hours, about 18 hours, about 20 hours, about 22 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 6 months, about 8 months, about 10 months, about 1 year, or more than about 1 year.

[0080] Training records can be constructed from sequences of observations. Such sequences can include a fixed length to facilitate data processing. For example, sequences can be zero padded or selected as an independent subset of a single patient's records.

[0081] The model may process the input features to generate output values ​​including one or more classifications, one or more predictions, or a combination thereof. For example, such classifications or predictions may include a binary classification of healthy / normal health (e.g., absence of disease or disorder) or adverse health (e.g., presence of disease or disorder), a classification between groups of categorical labels (e.g., "no disease or disorder", "definite disease or disorder", and "suspected disease or disorder"), the likelihood (e.g., relative likelihood or probability) of developing a particular disease or disorder, a score indicating the presence of a disease or disorder, a score indicating the level of systemic inflammation experienced by the patient, a "risk factor" indicating the patient's probability of death, a prediction of the time the patient is expected to develop the disease or disorder, and a confidence interval for any numerical prediction. Various machine learning techniques may be cascaded such that the output of the machine learning techniques may also be used as input features to subsequent layers or subsections of the model.

[0082] The model can be trained using a dataset to train the model (e.g., by determining model weights and correlations) to generate real-time classifications or predictions. Such a dataset can be large enough to generate statistically significant classifications or predictions. For example, the dataset can include a database of de-identified data, including dynamic biological response data and other measurements, as well as dynamic biological response data and other measurements from a hospital or other clinical environment.

[0083] The dataset may be divided into subsets (e.g., discrete or overlapping), such as a training dataset, an expanded dataset, and a test dataset. For example, the dataset may be divided into a training dataset that includes 80% of the dataset and a test dataset that includes 20% of the dataset. The training dataset may include about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% of the dataset. The expanded dataset may include about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% of the dataset. The test dataset may include about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% of the dataset. The training set (e.g., training data set) may be selected by random sampling of a set of data corresponding to one or more patient cohorts to ensure sampling independence. Alternatively, the training set (e.g., training data set) may be selected by proportional sampling of a set of data corresponding to one or more patient cohorts to ensure sampling independence.

[0084] To improve the accuracy of model prediction and reduce overfitting of the model, the dataset may be augmented to increase the number of samples in the training set. For example, data augmentation may include rearranging the order of observations in the training records. To accommodate a dataset with missing observations, methods of imputing missing data, such as forward filling, backfilling, linear interpolation, and multitask Gaussian processes, may be used. To remove confounding factors, the dataset may be filtered. For example, a subset of patients may be excluded within the database.

[0085] The model may include one or more neural networks, such as a neural network, a convolutional neural network (CNN), a deep neural network (DNN), a recurrent neural network (RNN), or a deep RNN. The recurrent neural network may include units that may be long short-term memory (LSTM) units or gated recurrent units (GRUs). For example, the model may include an algorithmic architecture that includes a neural network with a set of input features, such as vital signs and other measurements, a patient's medical history, and / or a patient's demographics. Neural network techniques, such as dropout or regularization, may be used during training of the model to prevent overfitting. The neural network may include multiple sub-networks, each configured to generate a classification or prediction of a different type of output information (e.g., may be combined to form an overall output of the neural network). The model may alternatively utilize statistical or related algorithms, including random forests, classification and regression trees, support vector machines, discriminant analysis, regression techniques, and ensembles and gradient boosted variations thereof.

[0086] When the model generates a classification or prediction of a disease or disorder, a notification (e.g., an alert or alarm) may be generated and sent to a health care provider, such as a doctor, nurse, or other member of the patient's treatment team in a hospital. The notification may be sent via an automated phone call, a short message service (SMS) or multimedia message service (MMS) message, an email, or an alert in a dashboard. The notification may include output information such as a prediction of the disease or disorder, a predicted likelihood of the disease or disorder, a time to expected onset of the disease or disorder, a confidence interval of the likelihood or time, or a recommended course of treatment for the disease or disorder.

[0087] To validate the performance of the model, different performance metrics can be generated. For example, the area under the receiver operating curve (AUROC) can be used to determine the diagnostic ability of the model. For example, the model can use a classification threshold that is adjustable, thereby making the specificity and sensitivity adjustable, and the receiver operating curve (ROC) can be used to identify different operating points that correspond to different values ​​of specificity and sensitivity.

[0088] In some cases, such as when the dataset is not large enough, cross-validation may be performed to assess the robustness of the model across different training and testing datasets.

[0089] The following definitions may be used to calculate performance metrics such as sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), AUPRC, AUROC, etc. A "false positive" may refer to an outcome in which a positive outcome or result is generated incorrectly or prematurely (e.g., before or without the actual onset of a disease or disorder). A "true positive" may refer to an outcome in which a positive outcome or result is generated correctly when the patient has a disease or disorder (e.g., the patient exhibits symptoms of a disease or disorder or the patient's records indicate the disease or disorder). A "false negative" may refer to an outcome in which a negative outcome or result is generated but the patient has a disease or disorder (e.g., the patient exhibits symptoms of a disease or disorder or the patient's records indicate the disease or disorder). A "true negative" may refer to an outcome in which a negative outcome or result is generated (e.g., before or without the actual onset of a disease or disorder).

[0090] The model may be trained until certain predefined conditions for accuracy or performance are met, such as having a minimum desired value corresponding to a diagnostic accuracy measure. For example, a diagnostic accuracy measure may correspond to a prediction of the likelihood of occurrence of a disease or disorder in a subject. As another example, a diagnostic accuracy measure may correspond to a prediction of the likelihood of a worsening or recurrence of a disease or disorder for which a subject has previously been treated. Examples of diagnostic accuracy measures may include sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, area under the precision-recall curve (AUPRC), and area under the receiver operating characteristic (ROC) curve (AUC) (AUROC), which correspond to the diagnostic accuracy of detecting or predicting a disease or disorder.

[0091] For example, such a predetermined condition can be one in which the sensitivity for predicting a disease or disorder includes a value of, e.g., at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0092] As another example, such a predetermined condition can be one in which the specificity for predicting a disease or disorder comprises a value of, e.g., at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0093] As another example, such a predetermined condition can be one in which the positive predictive value (PPV) for predicting a disease or disorder includes a value of, e.g., at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0094] As another example, such a predetermined condition can be a condition in which the negative predictive value (NPV) for predicting a disease or disorder includes a value, e.g., at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0095] As another example, such a predetermined condition can be one in which the area under the receiver operating characteristic (ROC) curve (AUC) (AUROC) predicting the disease or disorder includes a value of at least about 0.50, at least about 0.55, at least about 0.60, at least about 0.65, at least about 0.70, at least about 0.75, at least about 0.80, at least about 0.85, at least about 0.90, at least about 0.95, at least about 0.96, at least about 0.97, at least about 0.98, or at least about 0.99.

[0096] As another example, such a predetermined condition can be one in which the area under the precision-recall curve (AUPRC) predicting a disease or disorder comprises a value of at least about 0.10, at least about 0.15, at least about 0.20, at least about 0.25, at least about 0.30, at least about 0.35, at least about 0.40, at least about 0.45, at least about 0.50, at least about 0.55, at least about 0.60, at least about 0.65, at least about 0.70, at least about 0.75, at least about 0.80, at least about 0.85, at least about 0.90, at least about 0.95, at least about 0.96, at least about 0.97, at least about 0.98, or at least about 0.99.

[0097] In some embodiments, a model can be trained or configured to predict a disease or disorder with a sensitivity of at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0098] In some embodiments, a model can be trained or configured to predict a disease or disorder with a specificity of at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0099] In some embodiments, a model can be trained or configured to predict a disease or disorder with a positive predictive value (PPV) of at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0100] In some embodiments, a model can be trained or configured to predict a disease or disorder with a negative predictive value (NPV) of at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0101] In some embodiments, the trained model may be trained or configured to predict a disease or disorder with an area under the receiver operating characteristic (ROC) curve (AUC) (AUROC) of at least about 0.50, at least about 0.55, at least about 0.60, at least about 0.65, at least about 0.70, at least about 0.75, at least about 0.80, at least about 0.85, at least about 0.90, at least about 0.95, at least about 0.96, at least about 0.97, at least about 0.98, or at least about 0.99.

[0102] In some embodiments, a model may be trained or configured to predict a disease or disorder with an area under the precision-recall curve (AUPRC) of at least about 0.10, at least about 0.15, at least about 0.20, at least about 0.25, at least about 0.30, at least about 0.35, at least about 0.40, at least about 0.45, at least about 0.50, at least about 0.55, at least about 0.60, at least about 0.65, at least about 0.70, at least about 0.75, at least about 0.80, at least about 0.85, at least about 0.90, at least about 0.95, at least about 0.96, at least about 0.97, at least about 0.98, or at least about 0.99.

[0103] The training dataset may be collected from training subjects (e.g., humans). Each training subject has a diagnosis status indicating diagnosed with a biological condition or not diagnosed with a biological condition. In some embodiments, the training subject is a child aged 5 years or younger (e.g., 5 years, 4 years, 3 years, 2 years, 1 year, 9 months, 6 months, 3 months, or 1 month or younger). The following training procedure may be performed for each training subject in the plurality of training subjects.

[0104] In some embodiments, training data (e.g., dynamic IHC data) may be generated from training biological samples. For each biological sample, a plurality of baseline locations on the training biological sample may be sampled and measurements may be generated therefrom to obtain a plurality of dynamic biological response samples. Each dynamic biological response sample in the corresponding plurality of dynamic biological response samples corresponds to a different location in the corresponding plurality of locations, and each location in the corresponding plurality of locations represents a different growth period of the corresponding biological sample. Each respective location of the biological sample is then analyzed (e.g., using a laser ablation inductively coupled plasma mass spectrometer (LA-ICP-MS), a fluorescence image sensor, or a Raman spectrometer) to obtain a plurality of traces. Each trace in the corresponding plurality of traces corresponds to an abundance measurement of a corresponding substance collectively determined over time from the corresponding plurality of dynamic biological response samples.

[0105] Respective second data sets may then be obtained by applying recurrent quantification analysis (RQA) or related methods to the corresponding plurality of traces to measure a corresponding set of features, each respective feature in the corresponding set of features being determined by the variability in the abundance of one or more substances in the corresponding plurality of traces.

[0106] An untrained or partially untrained model may then be generated having (i) a corresponding set of features of the second dataset for each respective training subject in the plurality of training subjects, and (ii) a corresponding diagnostic state of each training subject in the plurality of training subjects selected from among the first diagnostic state and the second diagnostic state, thereby obtaining a trained model. The trained model provides an indication as to whether the test subject has the first biological state based on the value of the features of the set of features obtained from the biological sample of the test subject. In some embodiments, the trained model is a neural network algorithm, a convolutional neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering model algorithm, a supervised clustering model algorithm, a regression model, or any combination or variation thereof, in particular including gradient boosting implementations of the described algorithms, e.g., gradient boosted decision trees. In some embodiments, the trained model predicts outcomes for a multinomial or binomial distribution. In some embodiments, the trained model can be used to make a binary prediction as to whether or not a sample is derived from a subject with a first biological condition, or can be a multinomial prediction that distinguishes subjects without a diagnosis from subjects with the first biological condition, or a second biological condition that is different from the first biological condition.

[0107] In some embodiments, the model is a neural network or a convolutional neural network, see Vincent et al., 2010, "Stacked denoising autoencoders: J Mach Learn Res 11, pp. 3371-3408; Larochelle et al., 2009, "Exploring strategies for training deep neural networks," J Mach Learn Res 10, pp. 1-40; and Hassoun, 1995, Fundamentals of Artificial Neural Networks, Massachusetts Institute of Technology, each of which is incorporated herein by reference.

[0108] SVM is described in Cristianini and Shawe-Taylor, 2000, “An Introduction to Support Vector Machines,” Cambridge University Press, Cambridge; the 5 thin Proceedings of the Annual ACM Workshop on Computational Learning Theory, Boser et al., 1992, "A training algorithm for optimal margin classifiers", ACM Press, Pittsburgh, Pa., pp. 142-152; Vapnik, 1998, Statistical Learning Theory, Wiley, New York; Mount, 2001, Bioinformatics: sequence and genome analysis, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Duda, Pattern Classification, Second Edition, 2001, John Wiley & Sons, Inc., pp. 259, 262-265; and Hastie, 2001, The Elements of Statistical Learning, Springer, New York; and Furey et al., 2000, Bioinformatics 16, 906-914, each of which is incorporated herein by reference in its entirety. When used for classification, SVMs separate a given set of binary labeled data using a hyperplane that is maximally far from the labeled data. When linear separation is not possible, SVMs can work in conjunction with the technique of "kernels" that automatically achieve a nonlinear mapping to the feature space. The hyperplane found by the SVM in the feature space corresponds to a nonlinear decision boundary in the input space.

[0109] Decision trees are reviewed by Duda, 2001, Pattern Classification, John Wiley & Sons, Inc., New York, pp. 395-396, which is incorporated herein by reference. Decision tree based methods divide the feature space into a set of rectangles and fit a model (such as a constant) to each. In some embodiments, the decision tree is a random forest regression. One particular algorithm that may be used is Classification and Regression Trees (CART). Other particular decision tree algorithms include, but are not limited to, ID3, C4.5, MART, and Random Forest. CART, ID3, and C4.5 are described in Duda, 2001, Pattern Classification, John Wiley & Sons, Inc., New York, pp. 396-408 and pp. 411-412, which are incorporated herein by reference. CART, MART, and C4.5 are described in Hastie et al., 2001, The Elements of Statistical Learning, Springer-Verlag, New York, Chapter 9, which is incorporated herein by reference in its entirety. Random forests are described in Breiman, 1999, "Random Forests-Random Features," Technical Report 567, Statistics Department, UC Berkeley, September 1999, which is incorporated herein by reference in its entirety.

[0110] Clustering (e.g., unsupervised and supervised clustering model algorithms) are described in Duda and Hart, Pattern Classification and Scene Analysis, 1973, John Wiley & Sons, Inc., New York (hereinafter "Duda 1973"), pages 211-256, which is incorporated herein by reference in its entirety. As described in section 6.7 of Duda 1973, the clustering problem is described as one of finding natural groupings in a data set. To identify natural groupings, two problems are addressed. First, a method is determined to measure the similarity (or dissimilarity) between two samples. This metric (similarity measure) is used to ensure that samples in one cluster are more similar to each other than samples in other clusters. Second, a mechanism is determined for partitioning the data into clusters using the similarity measure. Similarity measures are discussed in section 6.7 of Duda 1973, and one way to begin a clustering investigation is to define a distance function and calculate a matrix of distances between all pairs of samples in the training set. If distance were a good measure of similarity, the distance between reference entities in the same cluster would be significantly shorter than the distance between reference entities in different clusters. However, as described on page 215 of Duda 1973, clustering does not require the use of a distance metric. For example, a non-metric similarity function s(x,x') can be used to compare two vectors x and x'. Traditionally, s(x,x') is a symmetric function whose value is large when x and x' are "similar" in some way. An example of a non-metric similarity function s(x,x') is provided on page 218 of Duda 1973. Once a method for measuring "similarity" or "dissimilarity" between points in a data set has been chosen, clustering requires a criterion function that measures the clustering quality of any partition of the data. The partition of the data set that extremes the criterion function is used to cluster the data. See page 217 of Duda 1973. Criterion functions are discussed in section 6.8 of DUDA 1973.Recently, Duda et al.,Pattern Classification,2. nd edition, John Wiley & Sons, Inc., New York. Clustering is described in detail on pages 537-563. Details of clustering techniques can be found in Kaufman and Rousseeuw, 1990, Finding Groups in Data: An Introduction to Cluster Analysis, Wiley, New York, NY; Everitt, 1993, Cluster analysis (3d ed.), Wiley, New York, NY; and Backer, 1995, Computer-Assisted Reasoning in Cluster Analysis, Prentice Hall, Upper Saddle River, New Jersey, each of which is incorporated herein by reference. Certain exemplary clustering techniques that can be used in the present disclosure include, but are not limited to, hierarchical clustering (agglomerative clustering using nearest neighbor, farthest neighbor, average linkage, centroid, or sum of squares algorithms), k-means clustering, fuzzy k-means clustering algorithm, and Jarvis-Patrick clustering. In some embodiments, the clustering comprises unsupervised clustering, where no preconceptions are imposed about which clusters should be formed when the training set is clustered.

[0111] Regression models such as multicategory logit models are described in Agresti, An Introduction to Categorical Data Analysis, 1996, John Wiley & Sons, Inc., New York, Chapter 8, which is incorporated herein by reference in its entirety. In some embodiments, the model utilizes regressors as disclosed in Hastie et al., 2001, The Elements of Statistical Learning, Springer-Verlag, New York, which is incorporated herein by reference in its entirety. In some embodiments, gradient boosting models are used, for example, for the purposes of the classification algorithms described herein, and these gradient boosting models are described in Boehmke, Bradley; Greenwell, Brandon (2019). "Gradient Boosting". Hands-On Machine Learning with R. Chapman & Hall. pp. 221-245. ISBN 978-1-138-49568-5, which is incorporated herein by reference in its entirety. In some embodiments, ensemble modeling techniques are used, for example for the classification algorithms described herein, and these ensemble modeling techniques are described in the implementation of the classification models herein and explained in Zhou Zhihua (2012). Ensemble Methods: Foundations and Algorithms. Chapman and Hall / CRC. ISBN 978-1-439-83003-1, which is incorporated herein by reference in its entirety.

[0112] In some embodiments, the model is performed by a device executing one or more programs (e.g., one or more programs stored in non-persistent memory 111 or persistent memory 112 of FIG. 1 ) that include instructions to perform the data analysis. In some embodiments, the data analysis is performed by a system that includes at least one processor (e.g., processing core 102) and memory (e.g., one or more programs stored in non-persistent memory 111 or persistent memory 112) that include instructions to perform the data analysis.

[0113] Computer Systems The present disclosure provides a computer system programmed to implement the methods of the present disclosure. FIG. 4 shows a computer system 401 programmed or otherwise configured to, for example, stain a tooth sample, acquire a fluorescent image of the stained tooth sample, spatially analyze the fluorescent intensity across the stained tooth sample, generate a time profile of inflammation, process the data using a trained model, and determine the risk of a disease or disorder in a subject. The computer system 401 can coordinate various aspects of the sensor data analysis of the present disclosure, such as, for example, staining a tooth sample, acquiring a fluorescent image of the stained tooth sample, spatially analyze the fluorescent intensity across the stained tooth sample, generate a time profile of inflammation, measure the dynamics of the time profile, process data using a trained model, and predict the subject's diagnostic status for a disease or disorder. The computer system 401 can be a user's electronic device or a computer system located remotely to the electronic device. The electronic device can be a mobile electronic device.

[0114] The computer system 401 includes a central processing unit (CPU, also including "processor" and "computer processor" herein) 405, which may be a single-core or multi-core processor, or multiple processors for parallel processing. The computer system 401 also includes memory or memory locations 410 (e.g., random access memory, read-only memory, flash memory), an electronic storage unit 415 (e.g., hard disk), a communication interface 420 (e.g., network adapter) for communicating with one or more other systems, and peripheral devices 425, such as cache, other memory, data storage, and / or electronic display adapters. The memory 410, the storage unit 415, the interface 420, and the peripheral devices 425 are in communication with the CPU 405 through a communication bus (solid lines), such as a motherboard. The storage unit 415 may be a data storage unit (or data repository) for storing data. The computer system 401 may be operatively coupled to a computer network ("network") 430 with the aid of the communication interface 420. Network 430 may be the Internet, an Internet and / or an extranet, or an intranet and / or an extranet in communication with the Internet. In some cases, network 430 is a telecommunications and / or data network. Network 430 may include one or more computer servers, which may enable distributed computing, such as cloud computing. Network 430 may, in some cases, implement a peer-to-peer network with the aid of computer system 401, which may enable devices coupled to computer system 401 to operate as clients or servers.

[0115] CPU 405 may execute a sequence of machine-readable instructions, which may be embodied in a program or software. The instructions may be stored in a memory location, such as memory 410. The instructions may instruct CPU 405, which may then be programmed or otherwise configured to perform the methods of the present disclosure. Examples of operations performed by CPU 405 may include fetch, decode, execute, and write back.

[0116] The CPU 405 may be part of a circuit, such as an integrated circuit. One or more other components of the system 401 may be included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC).

[0117] The storage unit 415 can store files such as drivers, libraries, and saved programs. The storage unit 415 can store user data, such as user preferences and user programs. In some cases, the computer system 401 can include one or more additional data storage units that are external to the computer system 401, such as located on a remote server in communication with the computer system 401 through an intranet or the Internet.

[0118] Computer system 401 can communicate with one or more remote computer systems through network 430. For example, computer system 401 can communicate with a remote computer system of a user (e.g., a healthcare provider). Examples of remote computer systems include a personal computer (e.g., a portable PC), a slate or tablet PC (e.g., an Apple® iPad, a Samsung® Galaxy Tab), a phone, a smartphone (e.g., an Apple® iPhone, an Android-enabled device, a Blackberry®), or a personal digital assistant. A user can access computer system 401 through network 430.

[0119] The methods described herein may be implemented by machine (e.g., computer processor) executable code stored on electronic storage locations of computer system 401, such as, for example, on memory 410 or electronic storage unit 415. Machine executable or machine readable code may be provided in the form of software. During use, the code may be executed by processor 405. In some cases, the code may be retrieved from storage unit 415 and stored in memory 410 for immediate access by processor 405. In some situations, electronic storage unit 415 may be eliminated and machine executable instructions stored in memory 410.

[0120] The code may be pre-compiled and configured for use with a machine having a processor adapted to execute the code, or may be compiled during run-time. The code may be provided in a programming language that may be selected to allow the code to be executed in a pre-compiled or compiled manner.

[0121] Aspects of the systems and methods provided herein, such as the computer system 401, may be embodied in programming. Various aspects of the technology may be considered as "products" or "articles of manufacture" that are typically in the form of machine (or processor) executable code and / or associated data carried or embodied in a type of machine-readable medium. The machine executable code may be stored in an electronic storage unit, such as a memory (e.g., read-only memory, random access memory, flash memory) or a hard disk. A "storage" type medium may include any or all of the tangible memory of a computer, a processor, or associated modules of tangible memory, such as various semiconductor memories, tape drives, disk drives, etc., which may provide non-transitory storage for software programming at any time. All or portions of the software may be communicated over the Internet or various other telecommunications networks. Such communication may, for example, enable loading of the software from one computer or processor to another computer, such as a management server or host computer to the computer platform of an application server. Thus, other types of media that may carry software elements include light waves, radio waves, and electromagnetic waves, such as those used over various air links over physical interfaces between local devices, through wired and optical fixed line networks. Physical elements that carry such waves, such as wired or wireless links, optical links, etc., may also be considered software-bearing media. As used herein, unless limited to non-transitory tangible "storage" media, terms such as computer or machine "readable medium" refer to any medium that participates in providing instructions to a processor for execution.

[0122] Thus, a machine-readable medium such as a computer executable code may take many forms including, but not limited to, a tangible storage medium, a carrier wave medium, or a physical transmission medium. Non-volatile storage media include optical or magnetic disks such as any of the storage devices in any computer or the like that may be used to implement, for example, the databases shown in the figures. Volatile storage media include dynamic memory such as the main memory of such a computer platform. Tangible transmission media include coaxial cables, copper wire and fiber optics, including the wires that make up a bus within a computer system. Carrier wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications. Thus, common forms of computer readable media include, for example, a floppy disk, a flexible disk, a hard disk, a magnetic tape, any other magnetic medium, a CD-ROM, a DVD, or a DVD-ROM, any other optical medium, punch cards, paper tape, any other physical storage medium having a pattern of holes, a RAM, a ROM, a PROM, an EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave carrying data or instructions, a cable or link carrying such a carrier wave, or any other medium from which a computer may read programming code and / or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.

[0123] The computer system 401 can include or be in communication with an electronic display 435 that includes a user interface (UI) 440 for providing, for example, fluorescent image data, fluorescent intensity data, a time profile of inflammation, and machine learning classification. Examples of UIs include, but are not limited to, graphical user interfaces (GUIs) and web-based user interfaces.

[0124] The methods and systems of the present disclosure may be implemented by one or more algorithms. The algorithms may be implemented by software when executed by the central processing unit 405. The algorithms may, for example, stain tooth samples, acquire fluorescent images of the stained tooth samples, analyze the fluorescent intensity spatially across the stained tooth samples, generate a time profile of inflammation, process the data using a trained model, and determine a subject's risk of disease or disorder.

[0125] Although the methods described elsewhere herein depict steps or sets of operations according to embodiments, one of ordinary skill in the art will recognize many variations based on the teachings set forth herein. These steps may be completed in different orders. Steps may be added or omitted. Some steps may include sub-steps. Many steps may be repeated as many times as is beneficial.

[0126] One or more steps of each method or set of operations may be performed using one or more of the circuitry as described herein, e.g., logic circuitry such as a processor or programmable array logic for a field programmable gate array. For example, a circuitry may be programmed to provide one or more of each step of the method or set of operations, and the program may include program instructions stored on a computer readable memory, or programmed steps of a logic circuit, e.g., programmable array logic or a field programmable gate array. EXAMPLES

[0127] Example 1: Dynamic molecular profiling in dental samples to determine disease risk Using the disclosed method and system, molecular profiles in dental samples were generated and then analyzed to determine disease risk in subjects. In general, the temporal dynamics of biological responses (e.g., inflammation) were found to be imprinted in samples (e.g., dental samples). This temporal dynamics can be analyzed to determine disease risk in subjects. A dynamic molecular profile of C-reactive protein (CRP), a marker of inflammation, was generated. Using dental biomarkers, dynamic time series profiles of CRP and inflammation were generated during a period including fetal (prenatal) development and early childhood in two sets of children, the first set with autism spectrum disorder (37 cases) and the second set without autism spectrum disorder (77 controls). The time series CRP profiles were analyzed to reveal novel features of the dynamics of CRP signals, thereby accurately distinguishing autism cases from controls. For example, inflammation profiles present before 1 year of age were significantly different between cases and controls. In contrast, a clinical diagnosis of autism is usually made around the age of 3-4.

[0128] A primary tooth sample was obtained from each pediatric subject. The tooth sample was sectioned, demineralized, and an immunohistochemical stain (e.g., Dentine) was applied to the tooth sample. The immunohistochemical stain effectively mapped C-reactive protein (a molecular marker of inflammation) along the growth rings of the tooth sample, and developed a time profile of inflammation over the prenatal and postnatal periods. The time profile was analyzed using the machine learning algorithm of the present disclosure to train a highly accurate model to determine disease risk (e.g., autism).

[0129] FIG. 5 shows an example of a subject's daily C-reactive protein profile over time, with the y-axis showing CRP intensity and the x-axis showing developmental age. The developmental age of the pediatric subject includes the period from the second trimester of pregnancy (e.g., starting at 140 days prenatal, when the subject was in the prenatal stage) to approximately 6 months after birth. As shown in FIG. 5, the inflammatory (as indicated by CRP intensity) profile in autistic child cases was observed to be high prenatally.

[0130] 6A-6B show receiver operating characteristic (ROC) curves to characterize the sensitivity and specificity of a method for diagnosing autism at various predictive thresholds utilizing features derived from recurrent quantitative analysis of C-reactive protein profiles sampled prenatally and in early childhood (e.g., up to 1 year of age). FIG. 6A shows an empirical receiver operating characteristic (ROC) curve to evaluate the accuracy of the disclosed method for evaluating subjects for autism spectrum disorder. ROC curves can be used to evaluate the performance of a binary classifier. ROC curves are plotted as sensitivity (also called true positive rate) against specificity (also called true negative rate). A perfect classifier may have 100% sensitivity and 100% specificity, as well as an area under the curve (AUC) of 1.0. As shown in FIG. 6A, a classifier configured to determine the presence of autism in a subject based on a dynamic C-reactive protein profile had an area under the receiver operating characteristic (ROC) curve (AUC) of 0.86 with a 95% confidence interval (CI) of 0.72-1.00. Receiver operating characteristic (ROC) shows how the sensitivity and specificity value of a classifier changes as the threshold applied to the predicted probability of case state becomes higher or lower, and a lower threshold, for example, leads to more sensitive classification, but correspondingly lower specificity.As shown in Figure 6B, the main dynamic features that contribute to classifier performance, ranked in descending order of feature importance (e.g., as indicated by numerical feature weighting), include stratification, entropy, TT, MDL, RT1, RT2, Vmax, determinism, and Lmax.For example, stratification was determined to have higher feature importance than the others.

[0131] Thus, analysis of features derived from analysis of C-reactive protein profiles using the methods and systems of the present disclosure successfully determined disease risk for autism with an AUC of 0.86 using only features derived from analysis of C-reactive protein signatures measured on non-invasively obtained biological samples (e.g., dental samples) from pediatric subjects. These results demonstrate that early inflammatory response dynamics are later associated with disease and can be accurately detected and profiled using the methods and systems of the present disclosure.

[0132] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. The present invention is not intended to be limited by the specific examples provided within the specification. Although the present invention has been described with reference to the foregoing specification, the description and illustration of the embodiments herein are not intended to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the present invention. Furthermore, it should be understood that all aspects of the present invention are not limited to the specific depictions, configurations, or relative proportions set forth herein, which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the present invention described herein may be used in the practice of the present invention. It is therefore contemplated that the present invention will cover such alternatives, modifications, variations, or equivalents. The following claims define the scope of the present invention, and it is intended that methods and structures within the scope of these claims and their equivalents be covered thereby.

[0133] Embodiment Embodiment 1. A method for predicting a subject's diagnostic status with respect to a disease or disorder, the method comprising: (a) staining a tooth sample of the subject to produce a stained tooth sample; (b) analyzing fluorescence intensity spatially across the stained tooth sample; and (c) predicting the subject's diagnostic status with respect to the disease or disorder based at least in part on the analysis of the fluorescence intensity. Embodiment 2. The method of embodiment 1, wherein analyzing comprises obtaining a fluorescent image of the stained tooth sample and analyzing the fluorescent intensity of the fluorescent image. Embodiment 3. The method of embodiment 2, wherein acquiring a fluorescent image of the stained tooth sample comprises using an inverted or non-inverted confocal microscope. Embodiment 4. The method of any one of embodiments 1-3, wherein staining the tooth sample comprises using a C-reactive protein immunohistochemical stain. Embodiment 5. The method of any one of embodiments 1 to 4, further comprising sectioning the tooth sample. Embodiment 6. The method of any one of embodiments 1 to 5, wherein staining the tooth sample comprises demineralizing the tooth sample. Embodiment 7. The method of any one of embodiments 1-6, wherein the disease or disorder comprises autism spectrum disorder (ASD), attention-deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric kidney disease, kidney transplant rejection, pediatric cancer, or any combination thereof. Embodiment 8. The method of any one of embodiments 1 to 6, wherein the disease or disorder comprises an autism spectrum disorder. Embodiment 9. The method of any one of embodiments 1 to 8, wherein the subject is a human. Embodiment 10. The method of embodiment 9, wherein the subject is under 12 years of age. Embodiment 11. The method of embodiment 9, wherein the subject is under 1 year old. Embodiment 12. The method of embodiment 1, wherein analyzing comprises generating a time profile of inflammation based at least in part on the fluorescence intensity, and analyzing the time profile of inflammation. Embodiment 13 The method of embodiment 12, wherein at least a portion of the time profile of inflammation corresponds to the subject's prenatal period. Embodiment 14. The method of embodiment 1, wherein predicting the subject's diagnostic status with respect to a disease or disorder comprises processing the fluorescence intensity using a trained model. Embodiment 15. The method of embodiment 14, wherein the trained model is selected from the group consisting of a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering algorithm, a supervised clustering algorithm, a regression algorithm, a gradient boosting algorithm, and any combination thereof. Embodiment 16. The method of embodiment 14, wherein the trained model comprises a gradient boosted decision tree. Embodiment 17. The method of embodiment 14, wherein the trained model is configured to process one or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. Embodiment 18. The method of embodiment 17, wherein the trained model is configured to process two or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time (TT), maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. Embodiment 19. The method of embodiment 18, wherein the trained model predicts a diagnostic status for a disease or disorder with at least about 80% sensitivity. Embodiment 20. The method of embodiment 18, wherein the trained model predicts a diagnostic status for a disease or disorder with at least about 80% specificity. Embodiment 21. The method of embodiment 18, wherein the trained model predicts a diagnostic status for a disease or disorder with a positive predictive value of at least about 80%. Embodiment 22. The method of embodiment 18, wherein the trained model predicts a diagnostic status for a disease or disorder with a negative predictive value of at least about 80%. Embodiment 23. The method of embodiment 18, wherein the trained model predicts a diagnostic status for a disease or disorder with an area under the receiver operating characteristic curve (AUROC) of at least about 0.80. Embodiment 24. A device comprising one or more processors and a memory storing one or more programs for execution by the one or more processors, the one or more programs including instructions for: (a) sampling each respective position in a plurality of locations along a baseline on a biological sample of a subject associated with c-reactive protein of the subject, thereby obtaining a plurality of fluorescence intensity measurements, where each fluorescence intensity measurement in the plurality of fluorescence intensity measurements corresponds to a different position in the plurality of locations, where each position in the plurality of locations represents a different growth period of the biological sample of the subject associated with c-reactive protein; (b) analyzing each fluorescence intensity across the baseline on the biological sample, thereby obtaining a first data set; (c) deriving a respective second data set from the corresponding plurality of fluorescence intensity measurements, where each respective feature in a corresponding set of features is determined by successive variations in c-reactive protein fluorescence intensity; and (d) processing the features using a trained model to predict the subject's diagnostic status for a disease or disorder associated with c-reactive protein. Embodiment 25. A device as described in embodiment 24, wherein the multiple fluorescence intensity measurements are measured using an inverted or non-inverted confocal microscope. Embodiment 26. The device of embodiment 24 or 25, wherein the biological sample comprises a tooth sample. Embodiment 27. A device according to any one of embodiments 24 to 26, wherein the tooth sample is stained using C-reactive protein immunohistochemical staining. Embodiment 28. The device of embodiment 26, wherein the instructions further comprise sectioning the tooth sample. Embodiment 29. The device of embodiment 26, wherein the instructions further comprise demineralizing the tooth sample. Embodiment 30. The device of any one of embodiments 24 to 29, wherein the disease or disorder comprises autism spectrum disorder (ASD), attention deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric renal disease, renal transplant rejection, pediatric cancer, or any combination thereof. Embodiment 31. A device described in any one of embodiments 24 to 29, wherein the disease or disorder includes autism spectrum disorder (ASD). Embodiment 32. A device described in any one of embodiments 24 to 31, wherein the subject is a human. Embodiment 33. A device described in any one of embodiments 24 to 32, wherein the subject is under 12 years of age. Embodiment 34. A device described in any one of embodiments 24 to 32, wherein the subject is less than 1 year old. Embodiment 35. A device described in any one of embodiments 24 to 34, wherein analyzing includes generating a time profile of inflammation based at least in part on a plurality of fluorescence intensity measurements, and analyzing the time profile of inflammation. Embodiment 36 The device of embodiment 35, wherein at least a portion of the time profile of inflammation corresponds to the subject's prenatal period. Embodiment 37. A device described in any one of embodiments 24 to 36, wherein predicting the subject's diagnostic status with respect to a disease or disorder comprises processing a plurality of fluorescence intensity measurements using a trained model. Embodiment 38. The device of embodiment 37, wherein the trained model is selected from the group consisting of a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering algorithm, a supervised clustering algorithm, a regression algorithm, a gradient boosting algorithm, and any combination thereof. Embodiment 39. The device of embodiment 37, wherein the trained model comprises a gradient boosted decision tree. Embodiment 40. The device of embodiment 37, wherein the trained model is configured to process one or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. Embodiment 41. The device of embodiment 37, wherein the trained model is configured to process two or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time (TT), maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. Embodiment 42. A device described in any one of embodiments 24 to 41, wherein the trained model predicts a diagnostic status for a disease or disorder with a sensitivity of at least about 80%. Embodiment 43. A device described in any one of embodiments 24 to 41, wherein the trained model predicts a diagnostic status for a disease or disorder with a specificity of at least about 80%. Embodiment 44. A device described in any one of embodiments 24 to 41, wherein the trained model predicts a diagnostic status for a disease or disorder with a positive predictive value of at least about 80%. Embodiment 45. A device described in any one of embodiments 24 to 41, wherein the trained model predicts a diagnostic status for a disease or disorder with a negative predictive value of at least about 80%. Embodiment 46. A device described in any one of embodiments 24 to 41, wherein the trained model predicts a diagnostic status for a disease or disorder with an area under the receiver operating characteristic curve (AUROC) of at least about 0.80. Embodiment 47. A non-transitory computer readable storage medium and one or more computer programs embedded in the non-transitory computer readable storage medium, the one or more computer programs including instructions that, when executed by a computer system, cause the computer system to: (a) sample each respective position in a plurality of positions along a reference line on a biological sample of the subject associated with c-reactive protein of the subject, thereby obtaining a plurality of fluorescence intensity measurements, wherein each fluorescence intensity measurement in the plurality of positions corresponds to a different position in the plurality of positions, and each position in the plurality of positions corresponds to a different component of the biological sample of the subject associated with c-reactive protein. A non-transitory computer-readable storage medium and one or more computer programs embedded therein that cause a method to be performed that includes: (a) sampling a plurality of fluorescence intensity measurements representing a long period of time across a baseline on the biological sample, thereby obtaining a first data set; (b) analyzing each fluorescence intensity across a baseline on the biological sample, thereby obtaining a first data set; (c) deriving a respective second data set from a corresponding plurality of fluorescence intensity measurements, wherein each respective feature in a corresponding set of features is determined by the variability of c-reactive protein fluorescence intensity; and (d) processing the features using the trained model to predict a subject's diagnostic status with respect to a disease or disorder associated with c-reactive protein. Embodiment 48. The non-transitory computer-readable storage medium of embodiment 47, wherein the multiple fluorescence intensity measurements are measured using an inverted or non-inverted confocal microscope. Embodiment 49. The non-transitory computer-readable storage medium of claim 47 or 48, wherein the biological sample comprises a tooth sample. Embodiment 50. The non-transitory computer readable storage medium of claim 49, wherein the tooth sample is stained using a C-reactive protein immunohistochemical stain. Embodiment 51. The non-transitory computer readable storage medium of claim 49, wherein the method further comprises sectioning the tooth sample. Embodiment 52. A non-transitory computer-readable storage medium according to any one of embodiments 47 to 51, wherein the method further comprises demineralizing the tooth sample. Embodiment 53. A non-transitory computer-readable storage medium according to any one of embodiments 47 to 52, wherein the disease or disorder comprises autism spectrum disorder (ASD), attention-deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric renal disease, renal transplant rejection, pediatric cancer, or any combination thereof. Embodiment 54. A non-transitory computer-readable storage medium according to any one of embodiments 47 to 52, wherein the disease or disorder includes autism spectrum disorder (ASD). Embodiment 55. A non-transitory computer-readable storage medium according to any one of embodiments 47 to 54, wherein the subject is a human. Embodiment 56. A non-transitory computer-readable storage medium described in any one of embodiments 47 to 55, wherein the subject is under 12 years of age. Embodiment 57. A non-transitory computer-readable storage medium according to any one of embodiments 47 to 55, wherein the subject is less than 1 year old. Embodiment 58. A non-transitory computer-readable storage medium described in any one of embodiments 47 to 57, wherein analyzing includes generating a time profile of inflammation based at least in part on the multiple fluorescence intensity measurements, and analyzing the time profile of inflammation. Embodiment 59. The non-transitory computer-readable storage medium of embodiment 58, wherein at least a portion of the time profile of inflammation corresponds to a prenatal period of the subject. Embodiment 60. A non-transitory computer-readable storage medium according to any one of embodiments 47 to 59, wherein predicting a subject's diagnostic status with respect to a disease or disorder comprises processing a plurality of fluorescence intensity measurements using a trained model. Embodiment 61. The non-transitory computer-readable storage medium of embodiment 60, wherein the trained model is selected from the group consisting of a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering algorithm, a supervised clustering algorithm, a regression algorithm, a gradient boosting algorithm, and any combination thereof. Embodiment 62. The non-transitory computer-readable storage medium of embodiment 60, wherein the trained model comprises a gradient boosted decision tree. Embodiment 63. A non-transitory computer-readable storage medium as described in embodiment 60, wherein the trained model is configured to process one or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. Embodiment 64. A non-transitory computer-readable storage medium as described in embodiment 60, wherein the trained model is configured to process two or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time (TT), maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. Embodiment 65. A non-transitory computer-readable storage medium according to any one of embodiments 47 to 64, wherein the trained model predicts a diagnostic status for a disease or disorder with a sensitivity of at least about 80%. Embodiment 66. A non-transitory computer-readable storage medium according to any one of embodiments 47 to 64, wherein the trained model predicts a diagnostic status for a disease or disorder with a specificity of at least about 80%. Embodiment 67. The non-transitory computer-readable storage medium of embodiment 47, wherein the trained model predicts a diagnostic status for a disease or disorder with a positive predictive value of at least about 80%. Embodiment 68. The non-transitory computer-readable storage medium of embodiment 47, wherein the trained model predicts a diagnostic status for a disease or disorder with a negative predictive value of at least about 80%. Embodiment 69. The non-transitory computer-readable storage medium of embodiment 47, wherein the trained model predicts a diagnostic status for a disease or disorder with an area under the receiver operating characteristic curve (AUROC) of at least about 0.80. Embodiment 70. A method for training a model, comprising: a computer system having one or more processors and a memory storing one or more programs for execution by the one or more processors, the method comprising: (a) for each respective training subject in the plurality of training subjects, where a first subset of the training subjects in the plurality of training subjects have a first diagnostic status corresponding to having a first biological state associated with c-reactive protein, and a second subset of the training subjects in the plurality of training subjects have a second diagnostic status corresponding to not having the first biological state associated with c-reactive protein, (i) sampling each respective position in a plurality of positions along a reference line on the subject's biological sample associated with the subject's c-reactive protein, thereby obtaining a plurality of fluorescence intensity measurements, where each fluorescence intensity measurement in the plurality of fluorescence intensity measurements corresponds to a different position in the plurality of positions, and where each position in the plurality of positions corresponds to a different growth phase of the subject's biological sample associated with c-reactive protein. (ii) sampling a plurality of corresponding fluorescence intensity measurements across a baseline on the biological sample, thereby obtaining a first data set; and (iii) deriving a respective second data set from a corresponding plurality of fluorescence intensity measurements, wherein each respective feature in the corresponding set of features is determined by a continuous variation in c-reactive protein fluorescence intensity. (b) training an untrained or partially untrained model using (i) the corresponding set of features of the second data set for each respective training subject in the plurality of training subjects and (ii) a corresponding diagnostic state of each training subject in the plurality of training subjects selected from among a first diagnostic state and a second diagnostic state, thereby obtaining a trained model that provides an indication as to whether the test subject has a first biological state associated with c-reactive protein based on values ​​of the features in the set of features obtained from the biological sample associated with c-reactive protein of the test subject. Embodiment 71. The method of embodiment 70, wherein the trained model is a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering model algorithm, a supervised clustering model algorithm, a regression model, a gradient boosting algorithm, or any combination thereof. Embodiment 72. The method of embodiment 70, wherein the trained model is a multinomial classifier. Embodiment 73. The method of embodiment 70, wherein the trained model is a binary classifier. Embodiment 74. The method of any one of embodiments 70-73, wherein the first biological condition associated with c-reactive protein is selected from the group consisting of autism spectrum disorder (ASD), attention-deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric renal disease, kidney transplant rejection, and pediatric cancer. Embodiment 75. The method of embodiment 70, wherein the method further comprises evaluating the test subject for a first biological state associated with c-reactive protein by distinguishing between a first biological state associated with c-reactive protein and a second biological state associated with c-reactive protein that is different from the first biological state associated with metal metabolism. Embodiment 76 The method of embodiment 75, wherein the first biological condition is an autism spectrum disorder and the second biological condition is attention-deficit / hyperactivity disorder. Embodiment 77. The method of any one of embodiments 70 to 76, wherein the test subject is a human. Embodiment 78. The method of embodiment 77, wherein the human is under 12 years of age. Embodiment 79. The method of embodiment 78, wherein the human is under 1 year old. Embodiment 80. The method of any one of embodiments 70 to 79, wherein the corresponding biological sample associated with the c-reactive protein of each training subject is selected from the group consisting of hair shafts, teeth, and nails. Embodiment 81. The method of embodiment 80, wherein the corresponding biological sample associated with the c-reactive protein of each training subject is a hair shaft and the reference line corresponds to the longitudinal direction of the hair shaft. Embodiment 82. The method of any one of embodiments 70 to 79, wherein the corresponding biological sample associated with the c-reactive protein of each training subject is a tooth and the reference line corresponds to a direction across the growth zone, including the neonatal line of the tooth. Embodiment 83. The method of any one of embodiments 70 to 82, wherein the corresponding plurality of positions are arranged such that a first position in the corresponding plurality of positions along the corresponding biological sample associated with each training subject's c-reactive protein corresponds to a position closest to the leading edge of the corresponding biological sample associated with each training subject's c-reactive protein. Embodiment 84. A method according to any one of embodiments 70 to 79, wherein each trace in a corresponding plurality of fluorescence intensity measurements includes a plurality of data points, each data point being an instance of a respective position in the plurality of positions. Embodiment 85. The method of any one of embodiments 70 to 84, wherein the corresponding set of features is selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, propensity for recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof. Embodiment 86. The method of any one of embodiments 70 to 86, wherein the corresponding plurality of positions includes at least 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, or 5000, 6000, 7000, 8000, 9000, 10000, 12000, 14000, 16000, 18000, 20000, or more than 20000 positions.

Claims

1. 1. A method for predicting a subject's diagnostic status with respect to a disease or disorder, comprising: (a) staining a tooth sample of the subject to produce a stained tooth sample; (b) analyzing the fluorescence intensity spatially across the stained tooth sample; and (c) predicting the subject's diagnostic status with respect to said disease or disorder based at least in part on said analysis of said fluorescence intensities.

2. The method of claim 1 , wherein the analyzing comprises obtaining a fluorescent image of the stained tooth sample and analyzing the fluorescent intensity of the fluorescent image.

3. The method of claim 2 , wherein obtaining the fluorescent image of the stained tooth sample comprises using an inverted or non-inverted confocal microscope.

4. The method of claim 1 , wherein staining the tooth sample comprises using a C-reactive protein immunohistochemical stain.

5. The method of claim 1 further comprising sectioning the tooth sample.

6. The method of claim 1 , wherein staining the tooth sample comprises demineralizing the tooth sample.

7. 2. The method of claim 1, wherein the disease or disorder comprises autism spectrum disorder (ASD), attention-deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric renal disease, renal transplant rejection, pediatric cancer, or any combination thereof.

8. 10. The method of claim 1, wherein the disease or disorder comprises an autism spectrum disorder.

9. The method of claim 1 , wherein the subject is a human.

10. 10. The method of claim 9, wherein the subject is under 12 years of age.

11. 10. The method of claim 9, wherein the subject is less than 1 year old.

12. The method of claim 1 , wherein the analyzing comprises: generating a time profile of inflammation based at least in part on the fluorescence intensity; and analyzing the time profile of inflammation.

13. 13. The method of claim 12, wherein at least a portion of the time profile of inflammation corresponds to a prenatal period of the subject.

14. 2. The method of claim 1, wherein predicting the subject's diagnostic status with respect to the disease or disorder comprises processing the fluorescence intensities using a trained model.

15. 15. The method of claim 14, wherein the trained model is selected from the group consisting of a neural network algorithm, a support vector machine algorithm, a decision tree algorithm, an unsupervised clustering algorithm, a supervised clustering algorithm, a regression algorithm, a gradient boosting algorithm, and any combination thereof.

16. The method of claim 14 , wherein the trained model comprises a gradient boosted decision tree.

17. 15. The method of claim 14, wherein the trained model is configured to process one or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time, maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof.

18. 18. The method of claim 17, wherein the trained model is configured to process two or more features selected from the group consisting of recurrence rate, determinism, average diagonal length, maximum diagonal length, divergence, Shannon entropy in diagonal length, tendency to recurrence, stratification, trapping time (TT), maximum vertical line length, Shannon entropy in vertical line length, average recurrence time, Shannon entropy in recurrence time, number of most likely recurrences, mean diagonal length (MDL), recurrence time (RT), Vmax, determinism, Lmax, and any combination thereof.

19. 1. A device comprising one or more processors and a memory storing one or more programs for execution by said one or more processors, said one or more programs comprising: (a) sampling each respective location in a plurality of locations along a baseline on a biological sample of the subject associated with c-reactive protein of the subject, thereby obtaining a plurality of fluorescence intensity measurements, each fluorescence intensity measurement in the plurality of locations corresponding to a different location in the plurality of locations, each location in the plurality of locations representing a different development period of the biological sample of the subject associated with c-reactive protein; (b) analyzing each fluorescence intensity across a baseline on the biological sample, thereby obtaining a first data set; (c) deriving respective second data sets from the corresponding plurality of fluorescence intensity measurements, each respective feature in the corresponding set of features being determined by a successive variation in c-reactive protein fluorescence intensity; (d) using the trained model to process the features to predict the subject's diagnostic status with respect to a disease or disorder associated with c-reactive protein.

20. The device of claim 19 , wherein the plurality of fluorescence intensity measurements are measured using an inverted or non-inverted confocal microscope.

21. The device of claim 19 , wherein the biological sample comprises a tooth sample.

22. 22. The device of claim 21, wherein the tooth sample is stained using a C-reactive protein immunohistochemical stain.

23. 22. The device of claim 21, wherein the instructions further comprise sectioning the tooth sample.

24. 22. The device of claim 21, wherein the instructions further comprise demineralizing the tooth sample.

25. 20. The device of claim 19, wherein the disease or disorder comprises autism spectrum disorder (ASD), attention deficit / hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), schizophrenia, irritable bowel disease (IBD), pediatric renal disease, renal transplant rejection, pediatric cancer, or any combination thereof.

26. 20. The device of claim 19, wherein the disease or disorder comprises autism spectrum disorder (ASD).

27. The device of claim 19 , wherein the subject is a human.

28. 20. The device of claim 19, wherein the subject is under 12 years of age.

29. A non-transitory computer readable storage medium and one or more computer programs embodied in the non-transitory computer readable storage medium, the one or more computer programs including instructions that, when executed by a computer system, cause the computer system to: (a) sampling each respective location in a plurality of locations along a baseline on a biological sample of the subject associated with c-reactive protein of the subject, thereby obtaining a plurality of fluorescence intensity measurements, each fluorescence intensity measurement in the plurality of locations corresponding to a different location in the plurality of locations, each location in the plurality of locations representing a different development period of the biological sample of the subject associated with c-reactive protein; (b) analyzing each fluorescence intensity across a baseline on the biological sample, thereby obtaining a first data set; (c) deriving respective second data sets from the corresponding plurality of fluorescence intensity measurements, each respective feature in the corresponding set of features being determined by a variability in c-reactive protein fluorescence intensity; (d) processing the features using the trained model to predict the subject's diagnostic status with respect to a disease or disorder associated with c-reactive protein.

30. 1. A method for training a model, comprising:

1. A computer system having one or more processors and a memory storing one or more programs for execution by said one or more processors, (a) for each respective training subject in a plurality of training subjects, a first subset of training subjects in the plurality of training subjects having a first diagnostic status corresponding to having a first biological state associated with c-reactive protein, and a second subset of training subjects in the plurality of training subjects having a second diagnostic status corresponding to not having the first biological state associated with c-reactive protein; (i) sampling each respective location in a plurality of locations along a baseline on the biological sample of the training subject associated with c-reactive protein of the training subject, thereby obtaining a plurality of fluorescence intensity measurements, each fluorescence intensity measurement in the plurality of locations corresponding to a different location in the plurality of locations, each location in the plurality of locations representing a different development period of the biological sample of the training subject associated with c-reactive protein; (ii) analyzing each fluorescence intensity across the baseline on the biological sample, thereby obtaining a first data set; (iii) deriving respective second data sets from the corresponding plurality of fluorescence intensity measurements, each respective feature in the corresponding set of features being determined by a continuous variation in c-reactive protein fluorescence intensity; (b) training an untrained or partially untrained model using (i) a corresponding set of features of the second dataset for each respective training subject in the plurality of training subjects, and (ii) the corresponding diagnostic state of each training subject in the plurality of training subjects, selected from among the first diagnostic state and the second diagnostic state, thereby obtaining a trained model that provides an indication as to whether the test subject has the first biological state associated with c-reactive protein based on feature values ​​in a set of features obtained from a biological sample associated with c-reactive protein of the test subject.